Astrazeneca PLC 6-K, filed Apr 27, 2023
Astrazeneca PLC (AZN)
6-K
2023-04-27
For: 2023-04-27
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on April 27, 2023.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1. 1st Quarter Results
AstraZeneca
27 April
2023
Q1
2023 results
Strong start to the year with stable Total Revenue
and 15% growth excluding COVID-19 medicines[1]
Revenue
and EPS summary
|
|
|
|
Q1 2023
|
|
|
|
|
|
% Change
|
|
|
|
|
$m
|
Actual
|
|
|
-
Product Sales
|
|
10,566
|
(4)
|
1
|
|
- Alliance
Revenue[3]
|
|
286
|
88
|
90
|
|
- Collaboration Revenue3
|
|
27
|
(89)
|
(89)
|
|
Total
Revenue
|
|
10,879
|
(4)
|
-
|
|
Total Revenue ex COVID-19
|
|
10,725
|
10
|
15
|
|
Reported[4] EPS[5]
|
|
$1.16
|
>4x
|
>4x
|
|
Core[6] EPS
|
|
$1.92
|
1
|
6
|
- Reiterating guidance for FY 2023 Total Revenue and Core
EPS
Pascal Soriot, Chief Executive Officer, AstraZeneca,
said:
"AstraZeneca had a strong start to 2023, with Total Revenue
excluding COVID-19 medicines increasing 15%. Our performance in
Emerging Markets was particularly strong and I am impressed by the
growth and pace of innovation I see in China, which underscores the
competitive advantage of our leading presence in this country.
Our pipeline momentum continued with positive Phase III results for
a Lynparza-plus-Imfinzi combination in ovarian cancer, Imfinzi in
lung cancer, and promising new data for Enhertu across a range of
cancer types. Additionally, in the year to date we have started six
new Phase III trials and are on track to initiate 30 over the
course of 2023.
Finally, I would like to thank Leif Johansson for his outstanding
leadership during his time as Chair of the Board, and his
contribution to our return to growth strategy. Leif has been a
tremendous partner to me, and I look forward to building the same
strong partnership with our new Chair, Michel
Demaré."
Key milestones achieved since the prior results
As announced on 11 April 2023, AstraZeneca's results for Q2 2023
will include a gain of $718m in Core Other operating income
resulting from an update to the contractual relationships for
nirsevimab[13]
Guidance
The Company reiterates guidance for FY 2023 at CER, based on the
average exchange rates through 2022.
Total Revenue is expected to increase by a low-to-mid single-digit
percentage
Excluding COVID-19 medicines, Total Revenue is expected to increase
by a low double-digit percentage
The Company is unable to provide guidance on a Reported basis
because it cannot reliably forecast material elements of the
Reported results, including any fair value adjustments arising on
acquisition-related liabilities, intangible asset impairment
charges and legal settlement provisions. Please refer to the
cautionary statements section regarding forward-looking statements
at the end of this announcement.
Currency impact
If foreign exchange rates for April to December 2023 were to remain
at the average rates seen in the month of March 2023, it is
anticipated that FY 2023 Total Revenue and FY 2023 Core EPS would
both incur a low single-digit adverse impact versus the performance
at CER.
The Company's foreign exchange rate sensitivity analysis is
provided in Table 18.
Table 1: Key
elements of Total Revenue performance in Q1
2023
|
|
% Change
|
|
|
||||||
|
Revenue type
|
|
$m
|
Actual
|
CER
|
|
|
|||
|
Product Sales
|
|
10,566
|
(4)
|
1
|
|
∗ Decline of 4% (1% increase at
CER) impacted by lower sales of COVID-19 medicines
∗ Strong growth in Oncology, CVRM, R&I and Rare
Disease
|
|||
|
Alliance Revenue
|
|
286
|
88
|
90
|
|
∗ $220m for Enhertu (Q1 2022: $76m)
∗ $43m for Tezspire (Q1 2022: $3m)
∗ See Table 6 for further
details
|
|||
|
Collaboration Revenue
|
|
27
|
(89)
|
(89)
|
|
∗ No sales or regulatory milestones
from Lynparza in the quarter (Q1 2022:
$175m)
∗ See Table 7 for further
details
|
|||
|
Total Revenue
|
|
10,879
|
(4)
|
--
|
|
∗ Excluding COVID-19
medicines, Q1 2023
Total Revenue increased by 10% (15% at CER)
|
|||
|
Therapy areas
|
|
$m
|
Actual %
|
CER %
|
|
|
|||
|
Oncology
|
|
4,148
|
14
|
19
|
|
∗ Strong performance across key medicines and
regions
∗ No sales or regulatory milestones
from Lynparza in the quarter (Q1 2022:
$175m)
|
|||
|
CVRM6
|
|
2,557
|
15
|
22
|
|
∗ Farxiga up
32% (39% CER), Lokelma up 56% (64% at CER), roxadustat up 52% (66%
CER), Brilinta up 3% (5% at CER)
|
|||
|
R&I
|
|
1,633
|
3
|
8
|
|
∗ Fasenra up
10% (13% CER), Breztri up
67% (73% CER). Saphnelo and Tezspire continue to grow rapidly during their launch
phase
∗ Collaboration Revenue of $nil (Q1 2022: $70m,
relating to tralokinumab milestone)
|
|||
|
V&I[17]
|
|
355
|
(80)
|
(79)
|
|
∗ $127m from COVID-19 mAbs (Q1 2022:
$469m)
∗ $28m from Vaxzevria (Q1 2022: $1,145m)
|
|||
|
Rare Disease6
|
|
1,866
|
10
|
14
|
|
∗ Ultomiris up
55% (61% at CER), offset by decline in Soliris of 16% (13% at CER)
∗ Strensiq up
26% (28% at CER) reflecting strong patient demand and geographic
expansion
|
|||
|
Other Medicines
|
|
320
|
(26)
|
(21)
|
|
|
|||
|
Total Revenue
|
|
10,879
|
(4)
|
-
|
|
|
|||
|
Regions inc. COVID-19
|
|
$m
|
Actual %
|
CER %
|
|
|
|||
|
US
|
|
4,299
|
4
|
4
|
|
|
|||
|
Emerging Markets
|
|
3,162
|
(6)
|
1
|
|
∗ Growth rate impacted by lower sales of COVID-19
medicines (numbers ex. COVID-19 below)
|
|||
|
- China
|
|
1,602
|
(1)
|
8
|
|
|
|||
|
- Ex-China Emerging Markets
|
|
1,560
|
(10)
|
(6)
|
|
|
|||
|
Europe
|
|
2,162
|
(5)
|
-
|
|
|
|||
|
Established RoW
|
|
1,256
|
(22)
|
(12)
|
|
|
|||
|
Total Revenue inc. COVID-19
|
|
10,879
|
(4)
|
-
|
|
|
|||
|
Regions ex. COVID-19
|
|
$m
|
Actual %
|
CER %
|
|
|
|||
|
US
|
|
4,299
|
15
|
15
|
|
|
|||
|
Emerging Markets
|
|
3,136
|
14
|
22
|
|
|
|||
|
- China
|
|
1,602
|
2
|
11
|
|
∗ Third consecutive quarter of growth at
CER
∗ Recovery in inhaled products following lifting of
COVID-19 restrictions
|
|||
|
- Ex-China Emerging Markets
|
|
1,534
|
31
|
38
|
|
∗ Timing of Rare Disease tender
orders
|
|||
|
Europe
|
|
2,148
|
3
|
9
|
|
|
|||
|
Established RoW
|
|
1,142
|
(5)
|
7
|
|
|
|||
|
Total Revenue ex. COVID-19
|
|
10,725
|
10
|
15
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
Table 2: Key elements of financial performance in Q1
2023
|
Metric
|
Reported
|
Reported change
|
Core
|
Corechange
|
|
Comments[18]
|
|
Total Revenue
|
$10,879m
|
-4% Actual stable at CER
|
$10,879m
|
-4% Actual stable at CER
|
|
∗ Excluding COVID-19 medicines, Q1 2023 Total
Revenue increased by 10% (15% at CER)
∗ See Table 1 and the Total Revenue section of this
document for further details
|
|
Gross Margin[19]
|
82%
|
14pp Actual 14pp CER
|
83%
|
4pp Actual 4pp CER
|
|
+
Increasing mix of sales from Oncology and Rare Disease
medicines
+ Decreasing mix of Vaxzevria sales
‒ Increasing
mix of products with profit-sharing
arrangements
∗ Variations in Gross Margin can
be expected between periods due to product seasonality, foreign
exchange fluctuations, cost inflation and other
effects
|
|
R&D expense
|
$2,611m
|
22% Actual 28% CER
|
$2,300m
|
5% Actual 10% CER
|
|
+
Increased investment in the pipeline
+
Reported R&D expense was also impacted by intangible asset
impairments in Q1 2023, and by reversals of impairments in Q1
2022
∗ Core R&D-to-Total Revenue ratio of 21%(Q1
2022: 19%)
∗ Year-on-year comparisons can be impacted by
differences in cost phasing
|
|
SG&A expense
|
$4,059m
|
-16% Actual -13% CER
|
$3,054m
|
4% Actual 8% CER
|
|
+
Market development activities for recent launches
+
Core SG&A-to-Total Revenue ratio of 28%(Q1 2022:
26%).
‒ Reported
SG&A in Q1 2022 included a $775m charge for a legal settlement
with Chugai Pharmaceutical Co. Ltd
∗ Year-on-year comparisons can be impacted by
differences in cost phasing
|
|
Other operating income[20]
|
$379m
|
>3x Actual >3x CER
|
$318m
|
>3x Actual >3x CER
|
|
∗ Reported and Core OOI includes a gain of $241m
from the disposal of US rights to Pulmicort
Flexhaler
|
|
Operating Margin
|
23%
|
16pp Actual 16pp CER
|
36%
|
2pp Actual 1pp CER
|
|
∗ See Gross Margin, Expenses and OOIcommentary
above
|
|
Net finance expense
|
$287m
|
-10% Actual -8% CER
|
$240m
|
-4% Actual -3% CER
|
|
∗ Higher interest received on cash balances,
partially offset by higher rates on floating debt and bond
issuances
∗ Reported also impacted by a reduction in the
discount unwind on acquisition-related
liabilities
|
|
Tax rate
|
20%
|
-10pp Actual -10pp CER
|
20%
|
-1pp Actual -1pp CER
|
|
∗ Variations in the tax rate can be expected between
periods
|
|
EPS
|
$1.16
|
>4x Actual >4x CER
|
$1.92
|
1% Actual 6% CER
|
|
∗ Further details of differences between Reported
and Core are shown in Table 13
|
Table 3:
Pipeline highlights since prior results
announcement
|
Event
|
Medicine
|
Indication / Trial
|
Event
|
|
Regulatory approvals and other regulatory actions
|
Imfinzi +/- Imjudo
|
NSCLC (1st-line) (POSEIDON)
|
Regulatory approval (EU)
|
|
Imfinzi + Imjudo
|
Hepatocellular carcinoma (1st-line) (HIMALAYA)
|
Regulatory approval (EU)
|
|
|
Enhertu
|
HER2-positive breast cancer (2nd-line)
(DESTINY-Breast03)
|
Regulatory approval (CN)
|
|
|
Calquence
|
Maleate tablet formulation
|
Regulatory approval (EU)
|
|
|
Calquence
|
Mantle cell lymphoma
|
Regulatory approval (CN)
|
|
|
Ultomiris
|
NMOSD
|
Positive CHMP opinion (EU)
|
|
|
Regulatory submissionsor acceptances
|
Imfinzi
|
Biliary tract cancer (TOPAZ-1)
|
Regulatory submission (CN)
|
|
Enhertu
|
HER2+ breast cancer (3rd-line) (DESTINY-Breast02)
|
Regulatory submission (EU)
|
|
|
Beyfortus
|
RSV[21] (MELODY/MEDLEY)
|
Regulatory submission (JP)
|
|
|
eplontersen
|
ATTRv-PN[22] (NEURO-TTRansform)
|
Regulatory submission (US)
|
|
|
|
danicopan
|
PNH with EVH
|
Regulatory submission (EU)
|
|
Major Phase III data readouts and other developments
|
Lynparza + Imfinzi
|
Ovarian cancer (1st-line) (DUO-O)
|
Primary endpoint met
|
|
Imfinzi
|
NSCLC (neoadjuvant) (AEGEAN)
|
Dual primary endpoints met
|
Other pipeline updates
The Phase II/III trial for cotadutide daily formulation in NASH has
been discontinued due to portfolio prioritisation. Development
continues for AZD9550, a weekly injectable
GLP-1/glucagon.
In April, the ALXN1840 programme in Wilson Disease was terminated.
The decision was based on feedback from regulatory authorities on
review of data from the Wilson Disease programme, including the
Phase III FoCus and two Phase II mechanistic trials.
Table 4: New Phase III trials started since 1 January
2023
|
Medicine
|
Trial name
|
Indication
|
|
datopotamab deruxtecan
|
AVANZAR
|
NSCLC (1st-line)
|
|
TROPION-Lung07
|
Non-squamous NSCLC (1st-line)
|
|
|
camizestrant
|
CAMBRIA-1
|
HR-positive[23]/HER2-negative
adjuvant breast cancer
|
|
Tezspire
|
CROSSING
|
Eosinophilic oesophagitis
|
|
AZD3152
|
SUPERNOVA
|
COVID-19 prophylaxis
|
|
Ultomiris
|
ARTEMIS
|
Cardiac surgery associated acute kidney injury
|
Corporate and business development
In the quarter, AstraZeneca completed the previously-announced
acquisitions of CinCor Pharma Inc. (CinCor) and Neogene
Therapeutics Inc., and the disposal of US commercial rights
to Pulmicort
Flexhaler to
Cheplapharm.
AstraZeneca expanded its collaboration with SOPHiA GENETICS to
apply their multimodal technology and expertise to AstraZeneca's
oncology portfolio. The multimodal approach will combine radiomics
analysis of medical imaging data, molecular data, digital
pathology, clinical and biologic data for a more comprehensive
assessment of multimodal signatures.
In March 2023, AstraZeneca signed an investment agreement with
Qingdao High-tech Industrial Development Zone to build a production
and supply site in China for Breztri pressurised metered-dose inhalers. The
Qingdao plant will address the country's growing COPD burden. China
is home to about 100 million patients with COPD, which is the third
leading cause of death in the country.
In April 2023, the contractual relationship between AstraZeneca and
Swedish Orphan Biovitrum AB (Sobi) relating to future sales of
nirsevimab in the US was replaced by a royalty relationship between
Sanofi and Sobi. As a result, a liability representing
AstraZeneca's future obligations to Sobi will be eliminated from
AstraZeneca's Statement of Financial Position, and AstraZeneca will
record a gain of $718m in Core Other operating income in Q2
2023.
Sustainability summary
AstraZeneca published its ninth Sustainability Report and Data
Summary, along with the 2022 TCFD[24] Report
and related case studies. AstraZeneca also hosted an annual
Sustainability call for shareholders, reiterating its continued
commitment to deliver across our pillars; Access to Healthcare,
Environmental Protection and Ethics and Transparency. A recording
of the call and accompanying materials are available on the
AstraZeneca IR website.
Management changes
As previously communicated, Leif Johansson, will retire as Chair at
the conclusion of the Company's Annual General Meeting today, 27
April 2023. Michel Demaré's appointment as Chair will take
effect immediately on Leif's retirement, and Michel will step down
as a member of the Audit Committee.
Conference call
A conference call and webcast for investors and analysts will begin
today, 27 April 2023, at 11:45 UK time. Details can be accessed
via astrazeneca.com.
Reporting calendar
The Company intends to publish its half-year and second-quarter
results on Friday, 28 July 2023.
Operating and financial review
All narrative on growth and results in this section is based on
actual exchange rates, and financial figures are in US$ millions
($m), unless stated otherwise. The performance shown in this
announcement covers the three month period to 31 March 2023 ('the
quarter' or 'Q1 2023') compared to the three month period to 31
March 2022 ('Q1 2022'), unless stated otherwise.
Core financial measures, EBITDA, Net debt, Gross Margin, Operating
Margin and CER are non-GAAP financial measures because they cannot
be derived directly from the Group's Interim Financial Statements.
Management believes that these non-GAAP financial measures, when
provided in combination with Reported results, provide investors
and analysts with helpful supplementary information to understand
better the financial performance and position of the Group on a
comparable basis from period to period. These non-GAAP financial
measures are not a substitute for, or superior to, financial
measures prepared in accordance with GAAP.
Core financial measures are adjusted to exclude certain significant
items, such as:
Details on the nature of Core financial measures are provided on
page 62 of the Annual Report and Form
20-F Information 2022.
Reference should be made to the Reconciliation of Reported to Core
financial measures table included in the financial performance
section in this announcement.
Gross Margin is the percentage by which Product Sales exceeds the
Cost of Sales, calculated by dividing the difference between the
two by the sales figure. The calculation of Reported and Core Gross
Margin excludes the impact of Alliance Revenue and Collaboration
Revenue and any associated costs, thereby reflecting the underlying
performance of Product Sales.
EBITDA is defined as Reported Profit before tax after adding back
Net finance expense, results from Joint ventures and associates and
charges for Depreciation, amortisation and impairment. Reference
should be made to the Reconciliation of Reported Profit before tax
to EBITDA included in the financial performance section in this
announcement.
Net debt is defined as Interest-bearing loans and borrowings and
Lease liabilities, net of Cash and cash equivalents, Other
investments, and Net derivative financial instruments. Reference
should be made to Note 3 'Net debt' included in the Notes to the
Interim Financial Statements in this announcement.
The Company strongly encourages investors and analysts not to rely
on any single financial measure, but to review AstraZeneca's
financial statements, including the Notes thereto, and other
available Company reports, carefully and in their
entirety.
Due to rounding, the sum of a number of dollar values and
percentages in this announcement may not agree to
totals.
Total Revenue
Table 5:
Therapy area and medicine performance
|
|
Q1 2023
|
|
||||||
|
|
|
|
% Change
|
|
||||
|
Product Sales
|
|
$m
|
% Total
|
Actual
|
CER
|
|||
|
Oncology
|
|
3,920
|
36
|
16
|
21
|
|||
|
- Tagrisso
|
|
1,424
|
13
|
9
|
15
|
|||
|
- Imfinzi [25]
|
|
900
|
8
|
50
|
56
|
|||
|
- Lynparza
|
|
651
|
6
|
5
|
10
|
|||
|
- Calquence
|
|
532
|
5
|
28
|
31
|
|||
|
- Enhertu
|
|
37
|
-
|
>3x
|
>3x
|
|||
|
- Orpathys
|
|
8
|
-
|
(33)
|
(27)
|
|||
|
- Zoladex
|
|
227
|
2
|
(6)
|
3
|
|||
|
- Faslodex
|
|
75
|
1
|
(19)
|
(11)
|
|||
|
-
Others
|
|
66
|
1
|
(32)
|
(27)
|
|||
|
BioPharmaceuticals: CVRM
|
|
2,530
|
23
|
15
|
21
|
|||
|
- Farxiga
|
|
1,299
|
12
|
30
|
37
|
|||
|
- Brilinta
|
|
334
|
3
|
3
|
5
|
|||
|
- Lokelma
|
|
98
|
1
|
56
|
64
|
|||
|
-
roxadustat
|
|
61
|
1
|
49
|
63
|
|||
|
- Andexxa
|
|
44
|
-
|
34
|
42
|
|||
|
- Crestor
|
|
305
|
3
|
14
|
23
|
|||
|
- Seloken/Toprol-XL
|
|
179
|
2
|
(27)
|
(20)
|
|||
|
- Onglyza
|
|
63
|
1
|
(8)
|
(3)
|
|||
|
- Bydureon
|
|
45
|
-
|
(33)
|
(32)
|
|||
|
-
Others
|
|
102
|
1
|
4
|
9
|
|||
|
BioPharmaceuticals: R&I
|
|
1,583
|
15
|
5
|
10
|
|||
|
- Symbicort
|
|
688
|
6
|
2
|
7
|
|||
|
- Fasenra
|
|
338
|
3
|
10
|
13
|
|||
|
- Breztri
|
|
144
|
1
|
67
|
73
|
|||
|
- Saphnelo
|
|
47
|
-
|
>4x
|
>4x
|
|||
|
- Tezspire
|
|
11
|
-
|
n/m
|
n/m
|
|||
|
- Pulmicort
|
|
221
|
2
|
2
|
9
|
|||
|
- Bevespi
|
|
15
|
-
|
(1)
|
2
|
|||
|
- Daliresp/Daxas
|
|
13
|
-
|
(75)
|
(75)
|
|||
|
- Others
|
|
106
|
1
|
(27)
|
(22)
|
|||
|
BioPharmaceuticals: V&I
|
|
355
|
3
|
(80)
|
(78)
|
|||
|
-
COVID-19 mAbs
|
|
127
|
1
|
(73)
|
(70)
|
|||
|
- Vaxzevria
|
|
28
|
-
|
(97)
|
(97)
|
|||
|
- Synagis
|
|
198
|
2
|
(1)
|
5
|
|||
|
- FluMist
|
|
2
|
-
|
n/m
|
n/m
|
|||
|
Rare Disease
|
|
1,866
|
17
|
10
|
14
|
|||
|
- Soliris
|
|
834
|
8
|
(16)
|
(13)
|
|||
|
- Ultomiris
|
|
651
|
6
|
55
|
61
|
|||
|
- Strensiq
|
|
262
|
2
|
26
|
28
|
|||
|
- Koselugo
|
|
79
|
1
|
>2x
|
>2x
|
|||
|
- Kanuma
|
|
40
|
-
|
4
|
6
|
|||
|
Other Medicines
|
|
312
|
3
|
(26)
|
(21)
|
|||
|
- Nexium
|
|
244
|
2
|
(27)
|
(20)
|
|||
|
-
Others
|
|
68
|
1
|
(26)
|
(23)
|
|||
|
Product Sales
|
|
10,566
|
97
|
(4)
|
1
|
|||
|
Alliance Revenue
|
|
286
|
3
|
88
|
90
|
|||
|
Collaboration Revenue
|
|
27
|
-
|
(89)
|
(89)
|
|||
|
Total Revenue
|
|
10,879
|
100
|
(4)
|
-
|
|||
|
|
|
|
|
|
|
|
|
|
Table 6: Alliance Revenue
|
|
Q1 2023
|
||||
|
|
|
|
|
% Change
|
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Enhertu
|
|
220
|
77
|
>2x
|
>2x
|
|
Tezspire
|
|
43
|
15
|
n/m
|
n/m
|
|
Vaxzevria: royalties
|
|
-
|
-
|
n/m
|
n/m
|
|
Other royalty income
|
|
20
|
7
|
23
|
24
|
|
Other Alliance Revenue
|
|
3
|
1
|
>3x
|
>3x
|
|
Total
|
|
286
|
100
|
88
|
90
|
Table 7: Collaboration Revenue
|
|
Q1 2023
|
||||
|
|
|
|
|
% Change
|
|
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|
Farxiga: sales
milestones
|
|
24
|
89
|
n/m
|
n/m
|
|
Other Collaboration Revenue
|
|
3
|
11
|
(76)
|
(76)
|
|
Total
|
|
27
|
100
|
(89)
|
(89)
|
Table 8: Total Revenue by therapy area
|
|
Q1 2023
|
|
|||||
|
|
|
% Change
|
|
|
|||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
||
|
Oncology
|
|
4,148
|
38
|
14
|
19
|
||
|
BioPharmaceuticals
|
|
4,545
|
42
|
(19)
|
(15)
|
||
|
- CVRM
|
|
2,557
|
24
|
15
|
22
|
||
|
- R&I
|
|
1,633
|
15
|
3
|
8
|
||
|
- V&I
|
|
355
|
3
|
(80)
|
(79)
|
||
|
Rare Disease
|
|
1,866
|
17
|
10
|
14
|
||
|
Other Medicines
|
|
320
|
3
|
(26)
|
(21)
|
||
|
Total
|
|
10,879
|
100
|
(4)
|
-
|
||
|
|
|
|
|
|
|
|
|
Table 9: Total
Revenue by region
|
|
Q1 2023
|
|
|||||||
|
|
|
|
% Change
|
|
|||||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
||||
|
US
|
|
4,299
|
40
|
4
|
4
|
||||
|
Emerging Markets
|
|
3,162
|
29
|
(6)
|
1
|
||||
|
- China
|
|
1,602
|
15
|
(1)
|
8
|
||||
|
- Ex-China
|
|
1,560
|
14
|
(10)
|
(6)
|
||||
|
Europe
|
|
2,162
|
20
|
(5)
|
-
|
||||
|
Established RoW
|
|
1,256
|
12
|
(22)
|
(12)
|
||||
|
Total
|
|
10,879
|
100
|
(4)
|
-
|
||||
|
|
|
|
|
|
|
|
|
|
|
Table 10:
Total Revenue by region - excluding COVID-19
medicines
|
|
|
Q1 2023
|
|
|||||||
|
|
|
|
|
% Change
|
|
|||||
|
|
|
$m
|
% Total
|
Actual
|
CER
|
|||||
|
US
|
|
4,299
|
40
|
15
|
15
|
|||||
|
Emerging Markets
|
|
3,136
|
29
|
14
|
22
|
|||||
|
- China
|
|
1,602
|
15
|
2
|
11
|
|||||
|
- Ex-China
|
|
1,534
|
14
|
31
|
38
|
|||||
|
Europe
|
|
2,148
|
20
|
3
|
9
|
|||||
|
Established RoW
|
|
1,142
|
11
|
(5)
|
7
|
|||||
|
Total
|
|
10,725
|
100
|
10
|
15
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
Oncology Total Revenue increased by 14% (19% at CER) in Q1 2023 to
$4,148m and represented 38% of overall Total Revenue (Q1 2022:
32%). There was no Lynparza Collaboration Revenue in the quarter (Q1
2022: $175m) and Enhertu Alliance Revenue was $220m (Q1 2022: $76m).
Product Sales increased by 16% (21% at CER) in Q1 2023 to $3,920m,
reflecting new launches and increased patient access across key
brands; partially offset by declines in legacy
medicines.
Tagrisso
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
1,424
|
|
521
|
444
|
257
|
202
|
|
Actual change
|
|
9%
|
|
19%
|
9%
|
2%
|
(2%)
|
|
CER change
|
|
15%
|
|
19%
|
17%
|
8%
|
11%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Increased use of Tagrisso in adjuvant and 1st-line setting and
expansion of reimbursed access
|
|
US
|
|
∗ Increasing demand in 1st-line and adjuvant
setting, partially offset by unfavourable inventory
movements
|
|
Emerging Markets
|
|
∗ Rising demand from increased patient access in
China continues to offset NRDL[26] renewal
price reductions
∗ Recovery from Q4 2022 ordering dynamics in
China
|
|
Europe
|
|
∗ Established standard of care in
1st-line and adjuvant setting across EU5[27],
partially offset by pricing clawbacks in certain
markets
|
|
Established RoW
|
|
∗ Increased use in 1st-line setting and launch
acceleration in adjuvant, including Japan
|
Imfinzi
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
900
|
|
522
|
81
|
163
|
134
|
|
Actual change
|
|
50%
|
|
66%
|
39%
|
31%
|
33%
|
|
CER change
|
|
56%
|
|
66%
|
47%
|
38%
|
52%
|
|
|
|
|
|
|
|
|
|
|
Region
|
|
Drivers and commentary
|
|||||
|
Worldwide
|
|
∗ The Imfinzi revenue line includes sales
of Imjudo, which launched in Q4 2022 following
approvals in the US for patients with unresectable liver cancer
(HIMALAYA) and Stage IV NSCLC (POSEIDON)
∗ Increased use
of Imfinzi in
BTC[28] (TOPAZ-1),
liver cancer (HIMALAYA) and lung cancers (POSEIDON,
CASPIAN)
|
|||||
|
US
|
|
∗ Continued growth in new patient starts across
Stage III NSCLC and ES-SCLC[29]
∗ Strong launch in BTC following September 2022 FDA
approval, and growing penetration of Imfinzi + Imjudo in liver and lung
cancers
|
|||||
|
Emerging Markets
|
|
∗ Growth in ex-China driven increased market
penetration in ES-SCLC and NSCLC (PACIFIC), and recovery of
diagnosis and treatment rates following the COVID-19
pandemic
|
|||||
|
Europe
|
|
∗ Increased market penetration in ES-SCLC, launch
trajectory in BTC, growth in the number of reimbursed
markets
|
|||||
|
Established RoW
|
|
∗ New reimbursements, strong demand growth in
BTC
|
|||||
Lynparza
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
651
|
|
268
|
137
|
178
|
68
|
|
Actual change
|
|
(18%)
|
|
(1%)
|
13%
|
(47%)
|
2%
|
|
CER change
|
|
(14%)
|
|
(1%)
|
19%
|
(44%)
|
16%
|
|
Product Sales
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
651
|
|
268
|
137
|
178
|
68
|
|
Actual change
|
|
5%
|
|
(1%)
|
13%
|
11%
|
2%
|
|
CER change
|
|
10%
|
|
(1%)
|
19%
|
18%
|
16%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Lynparza remains
the leading medicine in the PARP[30] inhibitor
class globally across four tumour types, as measured by total
prescription volume
∗ No regulatory milestones received in Q1
2023
|
|
US
|
|
∗ Positive demand growth driven by OlympiA (FDA
approval March 2022) offset by flattening HRD testing rates in
ovarian cancer and destocking following an inventory build in Q4
2022 in anticipation of PROpel launch
|
|
Emerging Markets
|
|
∗ Re-enlistment
into China's NRDL
for ovarian cancer indications
(PSR[31] and
BRCAm[32] 1st-line
maintenance) and new enlistment in prostate cancer
(PROfound)
|
|
Europe
|
|
∗ Growth driven by increased uptake
in 1st-line HRD-positive ovarian cancer, gBRCAm[33] HER2-negative
early breast cancer and BRCAm mCRPC, partially offset by new
indication pricing impact and clawbacks in some
markets
|
|
Established RoW
|
|
∗ Growth continues across tumour
types
|
Enhertu
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
257
|
|
161
|
38
|
55
|
3
|
|
Actual change
|
|
>2x
|
|
>2x
|
>4x
|
>2x
|
>5x
|
|
CER change
|
|
>3x
|
|
>2x
|
>4x
|
>2x
|
>6x
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited
(Daiichi Sankyo) and AstraZeneca, amounted to $508m in the quarter
(Q1 2022: $166m)
∗ AstraZeneca's Total Revenue of $257m includes
$220m of Alliance Revenue from its share of gross profit and
royalties in territories where Daiichi Sankyo records product
sales
|
|
US
|
|
∗ US in-market sales, recorded by Daiichi Sankyo,
amounted to $336m in the quarter (Q1
2022: $119m)
∗ Rapid adoption as new standard of
care across all launched indications including HER2-low
mBC[34] with strong
demand continuing from breast cancer launches
|
|
Emerging Markets
|
|
∗ Strong uptake driven by new approvals and
launches
|
|
Europe
|
|
∗ Continued growth in 2nd-line and 3rd-line+
HER2-positive metastatic breast cancer
∗ Increased uptake following launches of 2nd-line+
HER2-positive gastric cancer and 2nd-line+ HER2-low metastatic
breast cancer after EU approvals in December 2022 and January 2023
respectively (DESTINY-Gastric01, DESTINY-Gastric02,
DESTINY-Breast04)
|
|
Established RoW
|
|
∗ In Japan, AstraZeneca receives a mid-single-digit
percentage royalty on sales made by Daiichi
Sankyo
|
Calquence
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
532
|
|
384
|
18
|
108
|
22
|
|
Actual change
|
|
28%
|
|
13%
|
>2x
|
95%
|
76%
|
|
CER change
|
|
31%
|
|
13%
|
>2x
|
>2x
|
91%
|
∗
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Increased penetration globally;
leading BTKi[35] in
key markets
|
|
US
|
|
∗ 1st-line patient share broadly stable, some
competitive impact in relapsed refractory
setting
∗ Q1 2023 performance impacted by destocking
following inventory build-up that followed approval of the maleate
tablet formulation
|
|
|
Orpathys
Total Revenue of $9m (Q1 2022: $11m) was driven by the 2021
launch in China, where Orpathys is approved for patients with lung cancer
and MET[36] gene
alterations. Orpathys is now included in the updated NRDL in China
for the treatment of patients with NSCLC with MET exon 14 skipping
alterations.
Other Oncology medicines
|
|
Q1 2023
|
Change
|
|
|||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
|
Zoladex
|
|
235
|
(5%)
|
4%
|
∗ Increased use in ex-China Emerging
Markets
|
|
|
Faslodex
|
|
75
|
(19%)
|
(11%)
|
∗ Generic competition
|
|
|
Other Oncology
|
|
66
|
(32%)
|
(27%)
|
∗ Includes Iressa, Arimidex, Casodex and other older
medicines
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals
BioPharmaceuticals Total Revenue decreased by 19% (15% at CER) in
Q1 2023 to $4,545m, representing 42% of overall Total Revenue (Q1
2022: 49%). The decrease was driven by declining revenues from
COVID-19 medicines. Growth from Farxiga and newer R&I medicines offset decreases
in some older medicines.
BioPharmaceuticals - CVRM
CVRM Total Revenue increased by 15% (22% at CER) to $2,557m in Q1
2023, driven by a strong Farxiga performance, and represented 24% of overall
Total Revenue (Q1 2022: 19%).
Farxiga
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
1,324
|
|
296
|
498
|
393
|
138
|
|
Actual change
|
|
32%
|
|
53%
|
27%
|
24%
|
39%
|
|
CER change
|
|
39%
|
|
53%
|
35%
|
31%
|
53%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Farxiga volume
is growing faster than the overall SGLT2[37] market
in all major regions
∗ Additional benefit from continued growth in the
overall SGLT2 inhibitor class
∗ Further HF[38] and
CKD[39] launches
and supportive updates to treatment guidelines including from
ESC[40] and
AHA[41]/ACC[42]/HFSA[43].
HF and CKD indications now launched in >100
markets
|
|
US
|
|
∗ Growth driven by HFrEF[44] and
CKD for patients with and without T2D[45]
∗ Favourable gross-to-net impact in the
quarter
∗ Farxiga continued
to gain in-class brand share, driven by HF and CKD
launches
|
|
Emerging Markets
|
|
∗ Growth despite generic competition in some
markets. Solid growth in ex-China Emerging Markets, particularly
Latin America
|
|
Europe
|
|
∗ Benefited from the addition of cardiovascular
outcomes trial data to the label, the HFrEF regulatory approval in
November 2020, and CKD regulatory approval in August 2021.
HFpEF[46] approval
in February 2023
∗ Continued strong volume growth in the quarter
partially offset by clawbacks
|
|
Established RoW
|
|
∗ In Japan, AstraZeneca sells to collaborator Ono
Pharmaceutical Co., Ltd, which records in-market sales. Continued
volume growth driven by HF and CKD launches. A milestone payment
from Ono was recorded in the quarter
|
Brilinta
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
334
|
|
179
|
82
|
67
|
6
|
|
Actual change
|
|
3%
|
|
8%
|
19%
|
(12%)
|
(59%)
|
|
CER change
|
|
5%
|
|
8%
|
25%
|
(7%)
|
(53%)
|
|
Region
|
|
Drivers and commentary
|
|
US
|
|
∗ Favourable comparison due to COVID-19 impact in Q1
2022
|
|
Emerging Markets
|
|
∗ Growth in all major Emerging Markets regions
following COVID-19 recovery
|
|
Europe
|
|
∗ European sales negatively impacted by
clawbacks
|
Lokelma
Total Revenue increased 56% (64% at CER) to $98m in Q1 2023.
Continued progress in Europe, with strong volume growth. In
China, Lokelma was enlisted to the NRDL in January 2022 and
is now the leading potassium binder in the
country.
roxadustat
Total Revenue increased 52% (66% at CER) to $62m, with roxadustat
benefitting from increased volumes in China following NRDL renewal
in 2022.
Andexxa
Total Revenue increased 2% (8% at CER) to $44m.
Other CVRM medicines
|
|
Q1 2023
|
Change
|
|
|||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
|
|
Crestor
|
|
306
|
14%
|
23%
|
∗ Strong sales growth in Emerging Markets, partly
offset by declines in the US and Established
RoW
|
|
|
Seloken
|
|
179
|
(27%)
|
(20%)
|
∗ Emerging Markets sales impacted
by China VBP implementation of Betaloc[47] oral
in H2 2021. Betaloc ZOK VBP
was implemented in Q4 2022
|
|
|
Onglyza
|
|
63
|
(8%)
|
(3%)
|
∗ Continued decline for DPP-IV
class
|
|
|
Bydureon
|
|
45
|
(33%)
|
(32%)
|
∗ Continued competitive
pressures
|
|
|
Other CVRM
|
|
102
|
4%
|
9%
|
|
|
|
|
|
|
|
|
|
|
BioPharmaceuticals - R&I
Total Revenue of $1,633m from R&I medicines in Q1 2023
increased 3% (8% at CER) and represented 15% of overall Total
Revenue (Q1 2022: 14%). This reflected growth in launch
brands: Fasenra, Tezspire, Breztri and Saphnelo.
Symbicort
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
688
|
|
233
|
229
|
147
|
79
|
|
Actual change
|
|
2%
|
|
(10%)
|
37%
|
(6%)
|
(14%)
|
|
CER change
|
|
7%
|
|
(10%)
|
48%
|
(1%)
|
(7%)
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Symbicort remains the global market leader within a
stable ICS[48]/LABA[49] class
|
|
US
|
|
∗ Market share resilience,
consolidating leadership in a declining ICS/LABA
market
∗ Generic entry expected in the US in
2023
|
|
Emerging Markets
|
|
∗ Post-COVID-19 recovery in
China and channel inventory rebuild
|
|
Europe
|
|
∗ Resilient market share in
growing ICS/LABA market, offset by pricing pressure
|
|
Established RoW
|
|
∗ Inventory destocking in some
markets and generic erosion in Japan
|
Fasenra
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
338
|
|
201
|
14
|
88
|
35
|
|
Actual change
|
|
10%
|
|
6%
|
>2x
|
17%
|
(4%)
|
|
CER change
|
|
13%
|
|
6%
|
>2x
|
23%
|
7%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Continues to be market leader in
severe eosinophilic asthma in major markets, and leads in the
IL-5[50] class
|
|
US
|
|
∗ Strong underlying demand
growth, partially offset in the quarter by inventory
dynamics
|
|
Emerging Markets
|
|
∗ Strong volume growth driven by
launch acceleration across key markets
|
|
Europe
|
|
∗ Expanded leadership in severe
eosinophilic asthma
|
|
Established RoW
|
|
∗ Maintained leadership of the
dynamic market[51] in
Japan
|
Breztri
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
144
|
|
81
|
38
|
15
|
10
|
|
Actual change
|
|
67%
|
|
53%
|
71%
|
>3x
|
52%
|
|
CER change
|
|
73%
|
|
53%
|
85%
|
>3x
|
73%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Continues to gain market share
within the growing FDC[52] triple
class across major markets
|
|
US
|
|
∗ Consistent share growth within the FDC
triple class in new-to-brand[53] and
total market
|
|
Emerging Markets
|
|
∗ Maintained market share
leadership in China within the FDC triple class
|
|
Europe
|
|
∗ Sustained growth across
markets as new launches continue to progress
|
|
Established RoW
|
|
∗ Increasing new-to-brand market share within
COPD plus ACO[54] in
Japan
|
Saphnelo
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
47
|
|
44
|
-
|
1
|
2
|
|
Actual change
|
|
>4x
|
|
>4x
|
n/m
|
>3x
|
>4x
|
|
CER change
|
|
>4x
|
|
>4x
|
n/m
|
>4x
|
>5x
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Demand acceleration in the US,
where Saphnelo has
new-to-brand leadership in the i.v.[55]
segment for SLE[56],
and the ongoing launches in Europe and Japan
|
Tezspire
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
54
|
|
43
|
-
|
7
|
4
|
|
Actual change
|
|
>10x
|
|
>10x
|
n/m
|
n/m
|
n/m
|
|
CER change
|
|
>10x
|
|
>10x
|
n/m
|
n/m
|
n/m
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Tezspire is
approved in the US, EU and Japan (as well as other countries) for
the treatment of severe asthma without biomarker or phenotypic
limitation.
∗ Amgen records sales in the US, and AstraZeneca
records its share of US gross profits as Alliance
Revenue
∗ AstraZeneca books Product Sales in markets outside
the US
∗ Combined sales of Tezspire by AstraZeneca and Amgen were $105m in the
quarter
|
|
US
|
|
∗ Increasing new-to-brand market share with majority
of patients new to biologics
|
|
Europe
|
|
∗ Achieved and maintained new-to-brand leadership in
key markets
∗ Pre-filled pen approved in January
2023
|
|
Established RoW
|
|
∗ Japan achieved new-to-brand leadership by month
two
|
Other R&I medicines
|
|
Q1 2023
|
% Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
||
|
Pulmicort
|
|
221
|
2%
|
9%
|
∗ Revenues increased in Emerging
Markets with continued recovery of nebulisation demand post
COVID-19 and market share in China stabilising
∗ Revenue from the US declined
54%
|
||
|
Bevespi
|
|
15
|
(1%)
|
2%
|
|
||
|
Daliresp
|
|
13
|
(75%)
|
(75%)
|
∗ Impacted by uptake of multiple
generics following loss of exclusivity in the US
|
||
|
Other R&I
|
|
113
|
(48%)
|
(45%)
|
∗ Collaboration Revenue of $nil (Q1 2022:
$70m)
∗ Product Sales of $106m decreased 27% (22% at CER)
due to generic competition
|
||
|
|
|
|
|
|
|
|
|
BioPharmaceuticals - V&I
Total Revenue from V&I medicines declined by 80% (79% at CER)
to $355m (Q1 2022: $1,814m) and represented 3% of overall Total
Revenue (Q1 2022: 16%).
COVID-19 mAbs
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
127
|
|
-
|
8
|
4
|
115
|
|
Actual change
|
|
(73%)
|
|
n/m
|
(91%)
|
(94%)
|
>10x
|
|
CER change
|
|
(70%)
|
|
n/m
|
(91%)
|
(94%)
|
>10x
|
|
Region
|
|
Drivers and commentary
|
|
US
|
|
∗ No revenue in the quarter following the completion
of US government contract deliveries in Q4 2022, and the revision
of Evusheld's emergency use authorisation in January
2023
|
|
Established RoW
|
|
∗ Deliveries in Japan
|
Vaxzevria
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
28
|
|
-
|
18
|
10
|
-
|
|
Actual change
|
|
(98%)
|
|
n/m
|
(97%)
|
(93%)
|
n/m
|
|
CER change
|
|
(97%)
|
|
n/m
|
(97%)
|
(92%)
|
n/m
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Revenue in the quarter decreased by 98% (97% at
CER) due to the conclusion of Vaxzevria contracts
|
Other V&I medicines
|
|
Q1 2023
|
% Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
|
||
|
Synagis
|
|
198
|
(1%)
|
5%
|
|
||
|
FluMist
|
|
2
|
n/m
|
n/m
|
∗ Normal
seasonality
|
||
|
|
|
|
|
|
|
|
|
Rare Disease
Total Revenue from Rare Disease medicines increased by 10% (14% at
CER) in Q1 2023 to $1,866m, representing 17% of overall Total
Revenue (Q1 2022: 15%).
Performance was driven by the durability of the
C5[57] franchise, Soliris and Ultomiris growth
in neurology indications and expansion into new
markets.
Soliris
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
834
|
|
448
|
115
|
183
|
88
|
|
Actual change
|
|
(16%)
|
|
(24%)
|
63%
|
(17%)
|
(18%)
|
|
CER change
|
|
(13%)
|
|
(24%)
|
77%
|
(12%)
|
(10%)
|
|
Region
|
|
Drivers and commentary
|
|
US
|
|
∗ Performance impacted by
successful conversion of Soliris patients
to Ultomiris in
PNH, aHUS[58] and
gMG[59],
partially offset by Soliris growth
in NMOSD
|
|
Emerging Markets
|
|
∗ Growth from expansion into new markets and
favourable timing of tender orders in some
markets
|
|
Europe,Established RoW
|
|
∗ Decline driven by successful conversion
of Soliris patients to Ultomiris, slightly offset by growth in
NMOSD
|
Ultomiris
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
651
|
|
381
|
13
|
159
|
98
|
|
Actual change
|
|
55%
|
|
73%
|
(46%)
|
52%
|
39%
|
|
CER change
|
|
61%
|
|
73%
|
(45%)
|
61%
|
61%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Performance driven by gMG launch in the US and
expansion into new markets
∗ Quarter-on-quarter variability in revenue growth
can be expected due to Ultomiris every eight-week dosing schedule and lower
average annual treatment cost per patient compared
to Soliris
|
|
US
|
|
∗ Performance driven by successful conversion
from Soliris across PNH, aHUS and gMG
|
|
Emerging Markets
|
|
∗ Impacted by inventory movements at third-party
distributors due to AstraZeneca bringing distribution
in-house
|
|
Europe
|
|
∗ Growth driven by strong demand generation
following new launch markets
|
|
Established RoW
|
|
∗ Rapid conversion from Soliris in Japan
|
Strensiq
|
Total Revenue
|
|
Worldwide
|
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
Q1 2023 $m
|
|
262
|
|
205
|
15
|
21
|
21
|
|
Actual change
|
|
26%
|
|
28%
|
70%
|
10%
|
7%
|
|
CER change
|
|
28%
|
|
28%
|
58%
|
17%
|
22%
|
|
Region
|
|
Drivers and commentary
|
|
Worldwide
|
|
∗ Performance driven by strong patient demand and
geographic expansion
|
Other Rare Disease medicines
|
|
Q1 2023
|
% Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
||
|
Koselugo
|
|
79
|
>2x
|
>2x
|
∗ Growth driven by expansion in new
markets
|
||
|
Kanuma
|
|
40
|
4%
|
6%
|
∗ Continued demand growth in ex-US
markets
|
||
|
|
|
|
|
|
|
|
|
Other medicines (outside the main therapy areas)
|
|
Q1 2023
|
% Change
|
|
||||
|
Total Revenue
|
|
$m
|
Actual
|
CER
|
Commentary
|
||
|
Nexium
|
|
248
|
(26%)
|
(20%)
|
∗ Generic launches in Japan in the latter part of
2022
|
||
|
Others
|
|
72
|
(26%)
|
(22%)
|
∗ Continued impact of generic
competition
|
||
|
|
|
|
|
|
|
|
|
Financial performance
Table 11:
Reported Profit and Loss
|
|
|
Q1 2023
|
Q1 2022
|
% Change
|
|
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Total Revenue
|
|
10,879
|
11,390
|
(4)
|
-
|
|
|
- Product Sales
|
|
10,566
|
10,980
|
(4)
|
1
|
|
|
- Alliance Revenue
|
|
286
|
152
|
88
|
90
|
|
|
- Collaboration Revenue
|
|
27
|
258
|
(89)
|
(89)
|
|
|
Cost of sales
|
|
(1,905)
|
(3,511)
|
(46)
|
(43)
|
|
|
Gross profit
|
|
8,974
|
7,879
|
14
|
19
|
|
|
Gross Margin
|
|
82.0%
|
68.0%
|
+14pp
|
+14pp
|
|
|
Distribution expense
|
|
(134)
|
(125)
|
7
|
12
|
|
|
% Total Revenue
|
|
1.2%
|
1.1%
|
-
|
-
|
|
|
R&D expense
|
|
(2,611)
|
(2,133)
|
22
|
28
|
|
|
% Total Revenue
|
|
24.0%
|
18.7%
|
-5pp
|
-5pp
|
|
|
SG&A expense
|
|
(4,059)
|
(4,840)
|
(16)
|
(13)
|
|
|
% Total Revenue
|
|
37.3%
|
42.5%
|
+5pp
|
+5pp
|
|
|
OOI[60] &
expense
|
|
379
|
97
|
>3x
|
>3x
|
|
|
% Total Revenue
|
|
3.5%
|
0.9%
|
+3pp
|
+2pp
|
|
|
Operating profit
|
|
2,549
|
878
|
>2x
|
>2x
|
|
|
Operating Margin
|
|
23.4%
|
7.7%
|
+16pp
|
+16pp
|
|
|
Net finance expense
|
|
(287)
|
(319)
|
(10)
|
(8)
|
|
|
Joint ventures and associates
|
|
-
|
(6)
|
(96)
|
(96)
|
|
|
Profit before tax
|
|
2,262
|
553
|
>4x
|
>4x
|
|
|
Taxation
|
|
(458)
|
(165)
|
>2x
|
>2x
|
|
|
Tax rate
|
|
20%
|
30%
|
|
|
|
|
Profit after tax
|
|
1,804
|
388
|
>4x
|
>4x
|
|
|
Earnings per share
|
|
$1.16
|
$0.25
|
>4x
|
>4x
|
|
|
|
|
|
|
|
|
|
Table 12:
Reconciliation of Reported Profit before tax to
EBITDA
|
|
|
Q1 2023
|
Q1 2022
|
% Change
|
|
|
|
|
|
$m
|
$m
|
Actual
|
CER
|
|
|
Reported Profit before tax
|
|
2,262
|
553
|
>4x
|
>4x
|
|
|
Net finance expense
|
|
287
|
319
|
(10)
|
(8)
|
|
|
Joint ventures and associates
|
|
-
|
6
|
(96)
|
(96)
|
|
|
Depreciation, amortisation and impairment
|
|
1,502
|
1,309
|
15
|
18
|
|
|
EBITDA
|
|
4,051
|
2,187
|
85
|
92
|
|
|
|
|
|
|
|
|
|
EBITDA for the comparative Q1 2022 was negatively impacted by
$1,180m unwind of inventory fair value uplift recognised on the
acquisition of Alexion. This unwind had $36m negative impact on Q1
2023 and will continue to be minimal in future
quarters.
Table 13:
Reconciliation of Reported to Core financial measures: Q1
2023
|
Q1 2023
|
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisitionof Alexion
|
Other
|
Core
|
Core
% Change
|
|
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
|
Gross profit
|
|
8,974
|
95
|
8
|
37
|
2
|
9,116
|
-
|
4
|
|
|
Gross Margin
|
|
82.0%
|
|
|
|
|
83.3%
|
+4pp
|
+4pp
|
|
|
Distribution expense
|
|
(134)
|
-
|
-
|
-
|
-
|
(134)
|
8
|
13
|
|
|
R&D expense
|
|
(2,611)
|
30
|
280
|
2
|
(1)
|
(2,300)
|
5
|
10
|
|
|
SG&A expense
|
|
(4,059)
|
41
|
954
|
2
|
8
|
(3,054)
|
4
|
8
|
|
|
Total operating expense
|
|
(6,804)
|
71
|
1,234
|
4
|
7
|
(5,488)
|
4
|
9
|
|
|
Other operating income & expense
|
|
379
|
(61)
|
-
|
-
|
-
|
318
|
>3x
|
>3x
|
|
|
Operating profit
|
|
2,549
|
105
|
1,242
|
41
|
9
|
3,946
|
-
|
4
|
|
|
Operating Margin
|
|
23.4%
|
|
|
|
|
36.3%
|
+2pp
|
+1pp
|
|
|
Net finance expense
|
|
(287)
|
-
|
-
|
-
|
47
|
(240)
|
(4)
|
(3)
|
|
|
Taxation
|
|
(458)
|
(24)
|
(231)
|
(9)
|
(9)
|
(731)
|
(5)
|
(1)
|
|
|
EPS
|
|
$1.16
|
$0.05
|
$0.66
|
$0.02
|
$0.03
|
$1.92
|
1
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit and Loss drivers
Gross profit
- Positive mix effects. The increased contribution
from Rare Disease and Oncology medicines had a positive impact on
the Gross Margin. Vaxzevria sales, which are also dilutive to gross margin,
declined substantially
- Negative mix effects. The rising contribution of
Product Sales with profit sharing arrangements (Lynparza,
Enhertu and Tezspire) has a negative impact on gross margin
because AstraZeneca records product revenues in certain markets but
pays away half of the gross profit to its collaboration partners.
Emerging Markets, where gross margins tend to be below the Company
average, grew as a proportion of Total Revenue excluding COVID-19
medicines
-
Positive impact from cost of production in prior
periods
R&D expense
-
Recent positive data read outs for several high priority medicines
that have ungated late-stage trials
-
Investment in platforms, new technology and capabilities to enhance
R&D productivity
Reported R&D expense was also impacted by intangible asset
impairments in the quarter, and reversals of intangible asset
impairments in Q1 2022
SG&A expense
Other operating income
Reported Other operating income of $379m included a gain on the
disposal of the US rights to Pulmicort Flexhaler, disposal proceeds on the sale of tangible
assets, and royalties on certain medicines
Net finance expense
Taxation
-
On 23 March 2023, the UK Government presented the draft legislation
in relation to the new global minimum tax framework to the House of
Commons and this is now proceeding through the UK Parliamentary
process. This is expected to be brought into effect in the UK from
2024. The Company is currently assessing the potential impact of
these draft rules upon its financial statements
Table 14: Cash
Flow summary
|
|
|
Q1 2023
|
Q1 2022
|
Change
|
|
|
|
$m
|
$m
|
$m
|
|
Reported Operating profit
|
|
2,549
|
878
|
1,671
|
|
Depreciation, amortisation and impairment
|
|
1,502
|
1,309
|
193
|
|
Decrease in working capital and short-term provisions
|
|
242
|
1,804
|
(1,562)
|
|
Gains on disposal of intangible assets
|
|
(249)
|
(10)
|
(239)
|
|
Non-cash and other movements
|
|
(429)
|
(327)
|
(102)
|
|
Interest paid
|
|
(257)
|
(194)
|
(63)
|
|
Taxation paid
|
|
(225)
|
(228)
|
3
|
|
Net cash inflow from operating activities
|
|
3,133
|
3,232
|
(99)
|
|
Net cash inflow before financing activities
|
|
1,887
|
3,064
|
(1,177)
|
|
Net cash outflow from financing activities
|
|
(2,031)
|
(3,740)
|
1,709
|
In Q1 2022, the Reported Operating profit of $878m included a
negative impact of $1,180m relating to the unwind of the inventory
fair value uplift recognised on the acquisition of Alexion. This
was offset by a corresponding item (positive impact of $1,180m) in
Decrease in working capital and short-term provisions. Overall, the
unwind of the fair value uplift had no impact on Net cash inflow
from operating activities. This unwind had $36m negative impact on
Q1 2023 and will continue to be minimal in future
quarters.
The change in Net cash inflow before financing activities is
primarily driven by the movement in Purchase of intangible assets
of $1,079m, including the acquisition of CinCor, in the quarter to
31 March 2023.
The change in Net cash outflow from financing activities is
primarily driven by the issue of bonds of $3,826m, offset by the
repayment of loans and borrowings of $2,004m and dividends paid of
$3,047m in the quarter to 31 March 2023.
Included within Net cash inflow before financing activities is a
movement in the profit-participation liability of $175m, resulting
from the cash receipt from Sobi in Q1 2023 after achievement of a
regulatory milestone. The associated cash flow is presented within
investing activities.
Capital expenditure
Capital expenditure amounted to $247m in the quarter (Q1 2022:
$219m).
Table 15: Net
debt summary
|
|
|
At 31
Mar 2023
|
At 31
Dec 2022
|
At 31
Mar 2022
|
|
|
|
$m
|
$m
|
$m
|
|
Cash and cash equivalents
|
|
6,232
|
6,166
|
5,762
|
|
Other investments
|
|
230
|
239
|
61
|
|
Cash and investments
|
|
6,462
|
6,405
|
5,823
|
|
Overdrafts and short-term borrowings
|
|
(667)
|
(350)
|
(805)
|
|
Lease liabilities
|
|
(962)
|
(953)
|
(949)
|
|
Current instalments of loans
|
|
(2,958)
|
(4,964)
|
(1,264)
|
|
Non-current instalments of loans
|
|
(26,916)
|
(22,965)
|
(28,081)
|
|
Interest-bearing loans and borrowings (Gross debt)
|
|
(31,503)
|
(29,232)
|
(31,099)
|
|
Net derivatives
|
|
(21)
|
(96)
|
59
|
|
Net debt
|
|
(25,062)
|
(22,923)
|
(25,217)
|
Net debt increased by $2,139m in the quarter to date to $25,062m.
Details of the committed undrawn bank facilities are disclosed
within the going concern section of Note 1. Details of the
Company's solicited credit ratings are disclosed in Note
3.
Capital allocation
The Board's aim is to continue to strike a balance between the
interests of the business, financial creditors and the Company's
shareholders. The Company's capital allocation priorities include:
investing in the business and pipeline; maintaining a strong,
investment-grade credit rating; potential value-enhancing business
development opportunities; and supporting the progressive dividend
policy.
In approving the declaration of dividends, the Board considers both
the liquidity of the company and the level of reserves legally
available for distribution. Dividends are paid to shareholders from
AstraZeneca PLC, a Group holding company with no direct operations.
The ability of AstraZeneca PLC to make shareholder distributions is
dependent on the creation of profits for distribution and the
receipt of funds from subsidiary companies. The consolidated Group
reserves set out in the Condensed consolidated statement of
financial position do not reflect the profit available for
distribution to the shareholders of AstraZeneca PLC.
Summarised financial information for guarantee of securities of
subsidiaries
AstraZeneca Finance LLC ("AstraZeneca Finance") is the issuer of
0.700% Notes due 2024, 1.200% Notes due 2026, 1.750% Notes due
2028, 4.875% Notes due 2028, 4.900% Notes due 2030, 2.250% Notes
due 2031 and 4.875% Notes due 2033 (the "AstraZeneca Finance
Notes"). Each series of AstraZeneca Finance Notes has been fully
and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca
Finance is 100% owned by AstraZeneca PLC and each of the guarantees
by AstraZeneca PLC is full and unconditional and joint and
several.
The AstraZeneca Finance Notes are senior unsecured obligations of
AstraZeneca Finance and rank equally with all of AstraZeneca
Finance's existing and future senior unsecured and unsubordinated
indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca
Finance Notes is the senior unsecured obligation of AstraZeneca PLC
and ranks equally with all of AstraZeneca PLC's existing and future
senior unsecured and unsubordinated indebtedness. Each guarantee by
AstraZeneca PLC is effectively subordinated to any secured
indebtedness of AstraZeneca PLC to the extent of the value of the
assets securing such indebtedness. The AstraZeneca Finance Notes
are structurally subordinated to indebtedness and other liabilities
of the subsidiaries of AstraZeneca PLC, none of which guarantee the
AstraZeneca Finance Notes.
AstraZeneca PLC manages substantially all of its operations through
divisions, branches and/or investments in subsidiaries and
affiliates. Accordingly, the ability of AstraZeneca PLC to service
its debt and guarantee obligations is also dependent upon the
earnings of its subsidiaries, affiliates, branches and divisions,
whether by dividends, distributions, loans or
otherwise.
Please refer to the consolidated financial statements of
AstraZeneca PLC in our Annual Report on Form 20-F and reports on
Form 6-K with our quarterly financial results as filed or furnished
with the SEC[61] for
further financial information regarding AstraZeneca PLC and its
consolidated subsidiaries. For further details, terms and
conditions of the AstraZeneca Finance Notes please refer to
AstraZeneca PLC's reports on Form 6-K furnished to the SEC on 3
March 2023 and 28 May 2021.
Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the
Securities Act of 1933, as amended (the "Securities Act"), we
present below the summary financial information for AstraZeneca
PLC, as Guarantor, excluding its consolidated subsidiaries, and
AstraZeneca Finance, as the issuer, excluding its consolidated
subsidiaries. The following summary financial information of
AstraZeneca PLC and AstraZeneca Finance is presented on a combined
basis and transactions between the combining entities have been
eliminated. Financial information for non-guarantor entities has
been excluded. Intercompany balances and transactions between the
obligor group and the non-obligor subsidiaries are presented on
separate lines.
Table 16:
Obligor group summarised Statement of comprehensive
income
|
|
|
Q1 2023
|
Q1 2022
|
|
|
|
$m
|
$m
|
|
Total Revenue
|
|
-
|
-
|
|
Gross profit
|
|
-
|
-
|
|
Operating loss
|
|
-
|
(1)
|
|
Loss for the period
|
|
(237)
|
(155)
|
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
7,502
|
164
|
Table 17:
Obligor group summarised Statement of financial
position
|
|
|
At 31 Mar 2023
|
At 31 Mar 2022
|
|
|
|
$m
|
$m
|
|
Current assets
|
|
10
|
19
|
|
Non-current assets
|
|
-
|
-
|
|
Current liabilities
|
|
(2,952)
|
(1,682)
|
|
Non-current liabilities
|
|
(26,747)
|
(25,605)
|
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
14,067
|
8,652
|
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
(296)
|
(297)
|
Foreign exchange
The Company's transactional currency exposures on working-capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign exchange contracts against
the individual companies' reporting currency. Foreign exchange
gains and losses on forward contracts for transactional hedging are
taken to profit or loss. In addition, the Company's external
dividend payments, paid principally in pounds sterling and Swedish
krona, are fully hedged from announcement to payment
date.
Table 18:
Currency sensitivities
The Company provides the following currency-sensitivity
information:
|
|
|
|
Average
rates vs USD
|
|
Annual impact ($m) of 5% strengthening (FY2023 average rate vs FY 2022
average) [62]
|
|||||||||||||
|
Currency
|
Primary Relevance
|
|
FY 2022[63]
|
YTD 2023[64]
|
Change
(%)
|
Mar 2023[65]
|
Change[66]
(%)
|
|
Total Revenue
|
Core Operating Profit
|
||||||||
|
EUR
|
Total Revenue
|
|
0.95
|
0.93
|
2
|
0.93
|
2
|
|
323
|
159
|
||||||||
|
CNY
|
Total Revenue
|
|
6.74
|
6.85
|
(1)
|
6.90
|
(2)
|
|
309
|
174
|
||||||||
|
JPY
|
Total Revenue
|
|
131.59
|
132.35
|
(1)
|
133.77
|
(2)
|
|
181
|
122
|
||||||||
|
Other[67]
|
|
|
|
|
|
|
|
|
385
|
202
|
||||||||
|
GBP
|
Operating expense
|
|
0.81
|
0.82
|
(2)
|
0.82
|
(2)
|
|
46
|
(92)
|
||||||||
|
SEK
|
Operating expense
|
|
10.12
|
10.43
|
(3)
|
10.47
|
(3)
|
|
7
|
(55)
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Sustainability
Since the last quarterly report, AstraZeneca:
Access to healthcare
- New investment to build a manufacturing plant in
Qingdao city to produce Breztri pressurised metered-dose inhalers (pMDI) for
COPD patients in China. The local investment provides increased
access to a life-changing medicine for Chinese patients to meet a
very significant unmet need, and helps to tackle the burden of COPD
on the health system in China
-
Partnership with Shandong province to establish an innovative rare
diseases diagnosis and treatment hub
-
Partnership with the Chinese Red Cross Foundation to revitalise
rural parts of China through an RMB 30 million investment to
enhance health services and support disaster relief
Environmental protection
o
CEO Pascal Soriot convened the SMI Health Systems Task Force which
announced joint minimum climate and sustainability targets for
pharmaceutical suppliers in March 2023, to address greenhouse gas
emissions across the value chain and reduce the complexity for
suppliers of multiple requirements
o
The Company's commitment to reducing its Scope 3 indirect
greenhouse gas emissions is shown by its target of 95% of suppliers
by spend covering purchased goods and services and capital goods,
and 50% of suppliers by spend covering upstream transportation and
distribution and business travel, to have science-based targets by
the end of 2025. AstraZeneca was also recognised in March by CDP as
a 2022 Supplier Engagement Rating Leader
o
Committed to the Business Leaders' Open Call to Accelerate Action
on Water, which coincided with the UN 2023 Water Conference. The
Company's efforts are underpinned by a partnership with the WWF and
membership of the Alliance for Water Stewardship. AstraZeneca works
with suppliers and across sectors to improve water resilience,
focusing on 100 priority water basins. Starting in 2024, the
Company will invest $5 million per year to fund nature restoration
and water stewardship projects in the communities where it
operates. Details are included in the Biodiversity Statement,
published alongside the 2022 Sustainability Report and Data
Summary
o
Marked UN International Day of Forests by reflecting on AZ Forest
progress. AZ Forest is the Company's global initiative to plant and
maintain over 50 million trees worldwide by end of 2025, in
partnership with expert delivery partners focused on forest
landscape restoration, and by investing in community-led projects
adapted to the local context. More than 10.5 million trees have
been planted to date in Australia, Ghana, Indonesia, the UK and the
US
Ethics and transparency
Research and development
This section covers R&D events and milestones that have
occurred since the prior results announcement on 9 February 2023,
up to and including events on 26 April 2023.
A comprehensive view of AstraZeneca's pipeline of medicines in
human trials can be found in the latest clinical trials appendix,
available on www.astrazeneca.com/investor-relations.
The clinical trials appendix includes tables with details of the
ongoing clinical trials for AstraZeneca medicines and new molecular
entities in the pipeline.
Oncology
AstraZeneca presented new data across its diverse portfolio of
cancer medicines at two major medical congresses during the
quarter: the 2023 American Society of Clinical Oncology
Genitourinary Cancers Symposium (ASCO GU) in February and American
Association for Cancer Research (AACR) in April. At ASCO GU,
AstraZeneca presented 11 abstracts spanning three approved
medicines and four pipeline medicines. At AACR, AstraZeneca
presented 70 abstracts showcasing new data across 21 pipeline
molecules and eight marketed products across the oncology
portfolio.
AstraZeneca completed an exclusive global license agreement with
KYM Biosciences Inc. for CMG901, a potential first-in-class
antibody drug conjugate targeting Claudin 18.2, a promising
therapeutic target in gastric cancers, with a molecule monomethyl
auristatin E (MMAE) warhead. CMG901 is currently being evaluated in
a Phase I trial for the treatment of Claudin 18.2-positive solid
tumours, including gastric cancer with preliminary results showing
an encouraging profile for CMG901.
Tagrisso
|
Event
|
|
|
Commentary
|
|
Phase III trial read out
|
ADAURA
|
|
Met key secondary endpoint demonstrating statistically
significant and clinically meaningful improvement in
OS[68] compared
to placebo in the adjuvant treatment of patients with early-stage
EGFRm[69] NSCLC
after complete tumour resection with curative intent. (March
2023)
|
Imfinzi and Imjudo
|
Event
|
|
|
Commentary
|
|
Approval
|
EU
|
|
Imfinzi in combination
with Imjudo for the 1st-line treatment of adult patients
with advanced or unresectable HCC. (HIMALAYA, February
2023)
|
|
|
|
|
Imfinzi in combination
with Imjudo for the treatment of adult patients with
metastatic NSCLC. (POSEIDON, February 2023)
|
|
Presentation: AACR
|
AEGEAN
|
|
Results from interim EFS analysis of the AEGEAN Phase III trial,
presented at AACR, demonstrated statistically significant and
clinically meaningful 32% reduction in risk of disease recurrence,
progression events or death for Imfinzi in combination with neoadjuvant chemotherapy
before surgery and as adjuvant monotherapy after surgery versus
neoadjuvant chemotherapy alone followed by surgery for patients
with resectable early-stage NSCLC. (April 2023)
|
Lynparza
|
Event
|
|
|
Commentary
|
|
Presentation: ASCO GU
|
PROpel final OS
|
|
Results from the final prespecified OS analysis of the PROpel Phase
III trial, presented at ASCO GU,
demonstrated Lynparza in combination with abiraterone resulted in
median OS improvement of 7.4-months vs standard of care in mCRPC
(not statistically significant). (February
2023)
|
|
FDA ODAC
|
US
|
|
The FDA will convene a meeting of the ODAC on 28 April 2023 to
discuss the sNDA[70] for Lynparza in
combination with abiraterone for the treatment of mCRPC. (PROpel,
March 2023)
|
|
Phase III trial read-out
|
DUO-O (Lynparza and Imfinzi)
|
|
Met primary endpoint demonstrating a statistically significant and
clinically meaningful improvement in PFS versus chemotherapy plus
bevacizumab in newly diagnosed patients with advanced high-grade
epithelial ovarian cancer without tumour BRCA mutations. (April
2023)
|
Calquence
|
Event
|
|
|
Commentary
|
|
Approval
|
EU
|
|
Maleate tablet formulation. (ELEVATE-PLUS, February
2023)
|
|
Conditional approval
|
China
|
|
Patients with mantle cell lymphoma who have received at least one
prior therapy. (ACE-LY-004 and Phase I/II trial in Chinese
patients, March 2023)
|
Enhertu
|
Event
|
|
|
Commentary
|
|
Approval
|
China
|
|
Patients with unresectable or metastatic HER2-positive breast
cancer who have received one or more prior anti-HER2-based
regimens, based on DESTINY-Breast03 trial. (February
2023)
|
|
Phase II read out
|
DESTINY-PanTumor02
|
|
Met the prespecified target for objective response rate and
demonstrated durable response across multiple HER2-expressing
advanced solid tumours in heavily pre-treated patients.
(DESTINY-PanTumor02, March 2023)
|
BioPharmaceuticals - CVRM
eplontersen
|
Event
|
|
|
Commentary
|
|
Presentation: AAN
|
NEURO-TTRansform
|
|
Detailed results from the NEURO-TTRansform Phase III trial in
patients with hereditary transthyretin-mediated amyloid
polyneuropathy (ATTRv-PN) presented at the American Academy of
Neurology (AAN) 2023 Annual Meeting showed that eplontersen met all
co-primary and secondary endpoints at 66 weeks versus an external
placebo group. (April 2023).
|
cotadutide
|
Event
|
|
|
Commentary
|
|
Termination
|
PROXYMO ADVANCE
|
|
Strategic decision to discontinue the development of once-daily
cotadutide and focus on AZD9550, a once-weekly injectable GLP-1
glucagon co-agonist, and the broader NASH pipeline. (March
2023)
|
BioPharmaceuticals - R&I
Significant new trials that achieved first patient dosed during the
period included:
‒ CROSSING, a Phase III trial
of Tezspire in eosinophilic
oesophagitis
Fasenra
|
Event
|
|
|
Commentary
|
|
Phase III trial read-out
|
MIRACLE
|
|
Met the primary endpoint, demonstrating a statistically significant
reduction in annual asthma exacerbation rate (AAER) over 48 weeks
compared to placebo in patients in China with a history of
uncontrolled asthma.
|
|
Phase III trial read-out
|
TATE
|
|
Met the primary endpoints, demonstrating that the safety and
tolerability profile in severe eosinophilic asthma patients aged 6
to 11 years was consistent with previous trials in patients ages 12
years and older.
|
BioPharmaceuticals - V&I
AstraZeneca highlighted new data across its Vaccines and Immune
Therapies portfolio at the 33rd European Congress of Clinical
Microbiology & Infectious Diseases (ECCMID) in April 2023. The
company presented 15 abstracts, including four oral
presentations.
AZD3152
|
Event
|
|
|
Commentary
|
|
Presentation: ECCMID 2023
|
US
|
|
AstraZeneca presented the first in vitro neutralisation data on
AZD3152, including activity against past and currently circulating
COVID-19 variants. The data showed that AZD3152 neutralises all
known variants of concern to date. (April 2023)
|
Flumist
|
Event
|
|
|
Commentary
|
|
Regulatory approval
|
Japan
|
|
As previously announced in 2015, Daiichi Sankyo has responsibility
for the development and commercialisation
of FluMist Quadrivalent in
Japan, and holds the marketing authorisation following approval in
Japan in March 2023. AstraZeneca will
supply FluMist Quadrivalent to
Daiichi Sankyo, and will receive development milestones and
sales-related payments post launch. (March
2023)
|
Beyfortus
|
Event
|
|
|
Commentary
|
|
Publication: Nature
|
MELODY
|
|
Serum samples were collected from 2,143 infants to characterise the
duration of RSV nAb[71] levels
following nirsevimab administration. Nirsevimab recipients had RSV
nAb levels >140-fold higher than baseline at day 31, and
remained >50-fold
higher at day 151 and >7-fold higher at day 361. (April
2023)
|
|
Presentation: ECCMID 2023
|
MUSIC
|
|
At ECCMID 2023, AstraZeneca presented results from the MUSIC trial
for nirsevimab in immunocompromised children ≤ 24 months of
age. A single dose of nirsevimab was well tolerated and no safety
concerns arose over 151 days. (April 2023)
|
|
Contract update
|
|
|
In April 2023, AstraZeneca, Sanofi and Sobi simplified their
contractual arrangements relating to the development and
commercialisation of nirsevimab in the US. The updated arrangements
replaced the cash flows from AstraZeneca to Sobi with a royalty
relationship between Sanofi and Sobi. Sanofi continues to lead
commercialisation globally, and AstraZeneca will
co-promote Beyfortus in the UK, Germany, Italy, Spain, Japan and
China. (April 2023)
|
Rare Disease
Alexion, AstraZeneca Rare Disease, showcased the potential for its
pioneering therapies to redefine the treatment landscape for
certain rare neurological diseases at the American Academy of
Neurology (AAN) Annual Meeting. Alexion presented 18 abstracts,
including seven oral presentations, across generalised myasthenia
gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) and
dermatomyositis.
Ultomiris
|
Event
|
|
|
Commentary
|
|
Positive opinion
|
EU
|
|
Recommended for approval in the EU by CHMP for the treatment of
adults with NMOSD
|
ALXN1840
|
Event
|
|
|
Commentary
|
|
Termination
|
Wilson Disease programme
|
|
In April, the ALXN1840 programme in Wilson Disease was terminated.
The decision was based on feedback from regulators, on review of
data from the Wilson Disease programme, including the Phase III
FoCus and two Phase II mechanistic trials
|
Interim Financial Statements
Table 19: Condensed consolidated statement of comprehensive
income: Q1 2023
|
For the quarter ended 31 March
|
|
2023
|
2022
|
|
|
|
$m
|
$m
|
|
Total
Revenue[72]
|
|
10,879
|
11,390
|
|
Product Sales
|
|
10,566
|
10,980
|
|
Alliance Revenue
|
|
286
|
152
|
|
Collaboration Revenue
|
|
27
|
258
|
|
Cost of sales
|
|
(1,905)
|
(3,511)
|
|
Gross profit
|
|
8,974
|
7,879
|
|
Distribution expense
|
|
(134)
|
(125)
|
|
Research and development expense
|
|
(2,611)
|
(2,133)
|
|
Selling, general and administrative expense
|
|
(4,059)
|
(4,840)
|
|
Other operating income and expense
|
|
379
|
97
|
|
Operating profit
|
|
2,549
|
878
|
|
Finance income
|
|
78
|
17
|
|
Finance expense
|
|
(365)
|
(336)
|
|
Share of after tax losses in associates and joint
ventures
|
|
-
|
(6)
|
|
Profit before tax
|
|
2,262
|
553
|
|
Taxation
|
|
(458)
|
(165)
|
|
Profit for the period
|
|
1,804
|
388
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement of the defined benefit pension liability
|
|
(10)
|
335
|
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
|
46
|
18
|
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
|
2
|
-
|
|
Tax on items that will not be reclassified to profit or
loss
|
|
24
|
(94)
|
|
|
|
62
|
259
|
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign exchange arising on consolidation
|
|
314
|
(219)
|
|
Foreign exchange arising on designated liabilities in net
investment hedges
|
|
(7)
|
(32)
|
|
Fair value movements on cash flow hedges
|
|
56
|
5
|
|
Fair value movements on cash flow hedges transferred to profit and
loss
|
|
(75)
|
11
|
|
Fair value movements on derivatives designated in net investment
hedges
|
|
16
|
(8)
|
|
Tax on items that may be reclassified subsequently to profit or
loss
|
|
12
|
1
|
|
|
|
316
|
(242)
|
|
Other comprehensive income, net of tax
|
|
378
|
17
|
|
Total comprehensive income for the period
|
|
2,182
|
405
|
|
Profit attributable to:
|
|
|
|
|
Owners of the Parent
|
|
1,803
|
386
|
|
Non-controlling interests
|
|
1
|
2
|
|
|
|
1,804
|
388
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners of the Parent
|
|
2,181
|
405
|
|
Non-controlling interests
|
|
1
|
-
|
|
|
|
2,182
|
405
|
|
Basic earnings per $0.25 Ordinary Share
|
|
$1.16
|
$0.25
|
|
Diluted earnings per $0.25 Ordinary Share
|
|
$1.16
|
$0.25
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
|
1,549
|
1,548
|
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
|
1,560
|
1,561
|
Table 20:
Condensed consolidated statement of financial
position
|
|
|
At 31 Mar
2023
|
At 31 Dec
2022
|
At 31 Mar
2022
|
|
|
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
Property, plant and equipment
|
|
8,644
|
8,507
|
9,061
|
|
Right-of-use assets
|
|
955
|
942
|
954
|
|
Goodwill
|
|
20,001
|
19,820
|
19,963
|
|
Intangible assets
|
|
39,291
|
39,307
|
41,265
|
|
Investments in associates and joint ventures
|
|
77
|
76
|
63
|
|
Other investments
|
|
1,157
|
1,066
|
1,174
|
|
Derivative financial instruments
|
|
116
|
74
|
87
|
|
Other receivables
|
|
682
|
835
|
864
|
|
Deferred tax assets
|
|
3,498
|
3,263
|
4,195
|
|
|
|
74,421
|
73,890
|
77,626
|
|
Current assets
|
|
|
|
|
|
Inventories
|
|
4,967
|
4,699
|
7,624
|
|
Trade and other receivables
|
|
10,289
|
10,521
|
8,683
|
|
Other investments
|
|
230
|
239
|
61
|
|
Derivative financial instruments
|
|
40
|
87
|
54
|
|
Intangible assets
|
|
-
|
-
|
96
|
|
Income tax receivable
|
|
508
|
731
|
367
|
|
Cash and cash equivalents
|
|
6,232
|
6,166
|
5,762
|
|
Assets held for sale
|
|
-
|
150
|
-
|
|
|
|
22,266
|
22,593
|
22,647
|
|
Total assets
|
|
96,687
|
96,483
|
100,273
|
|
Liabilities
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(3,625)
|
(5,314)
|
(2,069)
|
|
Lease liabilities
|
|
(232)
|
(228)
|
(225)
|
|
Trade and other payables
|
|
(19,210)
|
(19,040)
|
(17,864)
|
|
Derivative financial instruments
|
|
(44)
|
(93)
|
(35)
|
|
Provisions
|
|
(546)
|
(722)
|
(1,423)
|
|
Income tax payable
|
|
(1,203)
|
(896)
|
(1,124)
|
|
|
|
(24,860)
|
(26,293)
|
(22,740)
|
|
Non-current liabilities
|
|
|
|
|
|
Interest-bearing loans and borrowings
|
|
(26,916)
|
(22,965)
|
(28,081)
|
|
Lease liabilities
|
|
(730)
|
(725)
|
(724)
|
|
Derivative financial instruments
|
|
(133)
|
(164)
|
(47)
|
|
Deferred tax liabilities
|
|
(2,795)
|
(2,944)
|
(5,626)
|
|
Retirement benefit obligations
|
|
(1,128)
|
(1,168)
|
(1,991)
|
|
Provisions
|
|
(914)
|
(896)
|
(949)
|
|
Other payables
|
|
(3,400)
|
(4,270)
|
(3,756)
|
|
|
|
(36,016)
|
(33,132)
|
(41,174)
|
|
Total liabilities
|
|
(60,876)
|
(59,425)
|
(63,914)
|
|
Net assets
|
|
35,811
|
37,058
|
36,359
|
|
Equity
|
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
|
|
Share capital
|
|
387
|
387
|
387
|
|
Share premium account
|
|
35,159
|
35,155
|
35,131
|
|
Other reserves
|
|
2,068
|
2,069
|
2,050
|
|
Retained earnings
|
|
(1,825)
|
(574)
|
(1,228)
|
|
|
|
35,789
|
37,037
|
36,340
|
|
Non-controlling interests
|
|
22
|
21
|
19
|
|
Total equity
|
|
35,811
|
37,058
|
36,359
|
Table 21:
Condensed consolidated statement of changes in
equity
|
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 Jan 2022
|
|
387
|
35,126
|
2,045
|
1,710
|
39,268
|
19
|
39,287
|
|
Profit for the period
|
|
-
|
-
|
-
|
386
|
386
|
2
|
388
|
|
Other comprehensive income
|
|
-
|
-
|
-
|
19
|
19
|
(2)
|
17
|
|
Transfer to other reserves
|
|
-
|
-
|
5
|
(5)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,046)
|
(3,046)
|
-
|
(3,046)
|
|
Issue of Ordinary Shares
|
|
-
|
5
|
-
|
-
|
5
|
-
|
5
|
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
182
|
182
|
-
|
182
|
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(474)
|
(474)
|
-
|
(474)
|
|
Net movement
|
|
-
|
5
|
5
|
(2,938)
|
(2,928)
|
-
|
(2,928)
|
|
At 31 Mar 2022
|
|
387
|
35,131
|
2,050
|
(1,228)
|
36,340
|
19
|
36,359
|
|
|
|
|
|
|
|
|
|
|
|
At 1 Jan 2023
|
|
387
|
35,155
|
2,069
|
(574)
|
37,037
|
21
|
37,058
|
|
Profit for the period
|
|
-
|
-
|
-
|
1,803
|
1,803
|
1
|
1,804
|
|
Other comprehensive income
|
|
-
|
-
|
-
|
378
|
378
|
-
|
378
|
|
Transfer to other reserves
|
|
-
|
-
|
(1)
|
1
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
-
|
-
|
(3,047)
|
(3,047)
|
-
|
(3,047)
|
|
Issue of Ordinary Shares
|
|
-
|
4
|
-
|
-
|
4
|
-
|
4
|
|
Share-based payments charge for the period
|
|
-
|
-
|
-
|
132
|
132
|
-
|
132
|
|
Settlement of share plan awards
|
|
-
|
-
|
-
|
(518)
|
(518)
|
-
|
(518)
|
|
Net movement
|
|
-
|
4
|
(1)
|
(1,251)
|
(1,248)
|
1
|
(1,247)
|
|
At 31 Mar 2023
|
|
387
|
35,159
|
2,068
|
(1,825)
|
35,789
|
22
|
35,811
|
Table 22:
Condensed consolidated statement of cash flows
|
For the quarter ended 31 March
|
|
2023
|
2022
|
|
|
$m
|
$m
|
|
|
Cash flows from operating activities
|
|
|
|
|
Profit before tax
|
|
2,262
|
553
|
|
Finance income and expense
|
|
287
|
319
|
|
Share of after tax losses of associates and joint
ventures
|
|
-
|
6
|
|
Depreciation, amortisation and impairment
|
|
1,502
|
1,309
|
|
Decrease in working capital and short-term provisions
|
|
242
|
1,804
|
|
Gains on disposal of intangible assets
|
|
(249)
|
(10)
|
|
Non-cash
and other movements
|
|
(429)
|
(327)
|
|
Cash generated from operations
|
|
3,615
|
3,654
|
|
Interest paid
|
|
(257)
|
(194)
|
|
Tax paid
|
|
(225)
|
(228)
|
|
Net cash inflow from operating activities
|
|
3,133
|
3,232
|
|
Cash flows from investing activities
|
|
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
|
(189)
|
-
|
|
Payments upon vesting of employee share awards attributable to
business combinations
|
|
(23)
|
(55)
|
|
Payment of contingent consideration from business
combinations
|
|
(214)
|
(182)
|
|
Purchase of property, plant and equipment
|
|
(247)
|
(219)
|
|
Disposal of property, plant and equipment
|
|
125
|
-
|
|
Purchase of intangible assets
|
|
(1,223)
|
(144)
|
|
Disposal of intangible assets
|
|
264
|
385
|
|
Movement in profit-participation liability
|
|
175
|
-
|
|
Purchase of non-current asset investments
|
|
-
|
(4)
|
|
Disposal of non-current asset investments
|
|
10
|
32
|
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
|
9
|
21
|
|
Payments to associates and joint ventures
|
|
-
|
(5)
|
|
Interest received
|
|
67
|
3
|
|
Net cash outflow from investing activities
|
|
(1,246)
|
(168)
|
|
Net cash inflow before financing activities
|
|
1,887
|
3,064
|
|
Cash flows from financing activities
|
|
|
|
|
Proceeds from issue of share capital
|
|
4
|
5
|
|
Issue of loans and borrowings
|
|
3,826
|
-
|
|
Repayment of loans and borrowings
|
|
(2,004)
|
(4)
|
|
Dividends paid
|
|
(3,047)
|
(2,971)
|
|
Hedge contracts relating to dividend payments
|
|
27
|
(77)
|
|
Repayment of obligations under leases
|
|
(67)
|
(74)
|
|
Movement in short-term borrowings
|
|
97
|
301
|
|
Payment of Acerta Pharma share purchase liability
|
|
(867)
|
(920)
|
|
Net cash outflow from financing activities
|
|
(2,031)
|
(3,740)
|
|
Net decrease in Cash and cash equivalents in the
period
|
|
(144)
|
(676)
|
|
Cash and cash equivalents at the beginning of the
period
|
|
5,983
|
6,038
|
|
Exchange rate effects
|
|
(11)
|
(9)
|
|
Cash and cash equivalents at the end of the period
|
|
5,828
|
5,353
|
|
Cash and cash equivalents consist of:
|
|
|
|
|
Cash and cash equivalents
|
|
6,232
|
5,762
|
|
Overdrafts
|
|
(404)
|
(409)
|
|
|
|
5,828
|
5,353
|
Notes to the Interim Financial Statements
Note 1: Basis of preparation and accounting policies
These unaudited condensed consolidated Interim financial statements
for the three months ended 31 March 2023 have been prepared in
accordance with International Accounting Standard 34, 'Interim
Financial Reporting' (IAS 34), as issued by the International
Accounting Standards Board (IASB), IAS 34 as adopted by the
European Union, UK-adopted IAS 34 and the Disclosure Guidance and
Transparency Rules sourcebook of
the United Kingdom's Financial Conduct Authority and with the
requirements of the Companies Act 2006 as
applicable to companies reporting under those
standards.
The unaudited Interim financial statements for the three months
ended 31 March 2023 were approved by
the Board of Directors for publication on 27 April
2023.
This results announcement does not constitute statutory accounts of
the Group within the meaning of sections
434(3) and 435(3) of the Companies Act 2006. The annual financial
statements of the Group for the year ended 31 December 2022 were
prepared in accordance with UK-adopted International Accounting
Standards and with the requirements of the Companies Act 2006. The
annual financial statements also comply fully with IFRSs as issued
by the IASB and International Accounting Standards as adopted by
the European Union. Except for the estimation of the interim income
tax charge, the Interim Financial Statements have been prepared
applying the accounting policies that were applied in the
preparation of the Group's published consolidated financial
statements for the year ended 31 December 2022.
The comparative figures for the financial year ended 31 December
2022 are not the Group's statutory accounts for that financial
year. Those accounts have been reported on by the Group's auditors
and will be delivered to the registrar of companies; their report
was (i) unqualified, (ii) did not include a reference to any
matters to which the auditors drew attention by way of emphasis
without qualifying their report, and (iii) did not contain a
statement under section 498(2) or (3) of the Companies Act
2006.
Alliance and Collaboration Revenues
Effective 1 January 2023, the Group has updated the presentation of
Total Revenue on the face of the Statement of Comprehensive Income
to include Alliance Revenue as a separate element to Collaboration
Revenue. Alliance Revenue, previously reported within Collaboration
Revenue, comprises income related to sales made by collaboration
partners, where AstraZeneca is entitled to a profit share, revenue
share or royalties, which are recurring in nature while the
collaboration arrangement remains in place. Alliance Revenue does
not include Product Sales where AstraZeneca is leading
commercialisation in a territory. Collaboration Revenue arising
from collaborative arrangements where the Group retains a
significant ongoing economic interest and receives upfront amounts
and event-triggered milestones, which arise from the licensing of
intellectual property, will continue to be reported as
Collaboration Revenue. In collaboration arrangements either
AstraZeneca or the collaborator acts as principal in sales to the
end customer. Where AstraZeneca acts as principal, we record 100%
of sales to the end customer within Product Sales. The revised
presentation reflects the increasing importance of income arising
from profit share arrangements where collaboration partners are
responsible for booking revenues in some or all
territories.
The comparative revenue reported in Q1 2023 relating to the quarter
to 31 March 2022 has been retrospectively adjusted to reflect the
new split of Total Revenue, resulting in Alliance Revenue being
reported for the quarter ending 31 March 2022 of $152m, however the
combined total of Alliance Revenue and Collaboration Revenue is
equal to the previously reported Collaboration Revenue total for
the quarter ending 31 March 2022.
Going concern
The Group has considerable financial resources available. As at 31
March 2023, the Group has $13.1bn in financial resources (Cash and
cash equivalent balances of $6.2bn and undrawn committed bank
facilities of $6.9bn available, of which $2.0bn of the facilities
are available until February 2025 and the other $4.9bn are
available until April 2026, with only $3.9bn of borrowings due
within one year). These facilities contain no financial covenants
and were undrawn at 31 March 2023.
The Group's revenues are largely derived from sales of medicines
covered by patents which provide a relatively high level of
resilience and predictability to cash inflows, although government
price interventions in response to budgetary constraints are
expected to continue to adversely affect revenues in some of our
significant markets. The Group, however, anticipates new revenue
streams from both recently launched medicines and those in
development, and the Group has a wide diversity of customers and
suppliers across different geographic areas.
Consequently, the Directors believe that, overall, the Group is
well placed to manage its business risks successfully. Accordingly,
they continue to adopt the going concern basis in preparing the
Interim Financial Statements.
Legal proceedings
The information contained in Note 5 updates the disclosures
concerning legal proceedings and contingent liabilities in the
Group's Annual Report and Form
20-F Information 2022.
Note 2: Intangible assets
In accordance with IAS 36 'Impairment of Assets', reviews for
triggers of impairment or impairment reversals at an individual
asset or cash generating unit level were conducted, and impairment
tests carried out where triggers were identified. As a result,
total net impairment charges of $271m have been recorded against
intangible assets during the three months ended 31 March 2023 (Q1
2022: $94m net reversal). Net impairment charges in respect of
medicines in development were $271m (Q1 2022: $77m reversal)
including the $244m impairment of the ALXN1840 intangible asset,
following decision to discontinue this development programme in
Wilsons disease.
The acquisition of CinCor completed on 24 February 2023, recorded
as an asset acquisition, with consideration and net assets acquired
of $1,268m, which included intangible assets acquired of $780m,
$424m of cash and cash equivalents, and $75m of marketable
securities. Contingent consideration of up to $496m could be
paid on achievement of regulatory milestones, those liabilities
will be recorded when milestones are triggered, or performance
conditions have been satisfied.
Note 3: Net debt
The table below provides an analysis of Net Debt and a
reconciliation of Net Cash Flow to the movement in Net Debt. The
Group monitors Net Debt as part of its capital-management policy as
described in Note 28 of the Annual Report and Form
20-F Information 2022. Net Debt
is a non-GAAP financial measure.
Table 23: Net
debt
|
|
|
At 1 Jan 2023
|
Cash flow
|
Acquisitions
|
Non-cash& other
|
Exchange movements
|
At 31 Mar 2023
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
|
(22,965)
|
(3,826)
|
-
|
(7)
|
(118)
|
(26,916)
|
|
Non-current instalments of leases
|
|
(725)
|
-
|
(6)
|
6
|
(5)
|
(730)
|
|
Total long-term debt
|
|
(23,690)
|
(3,826)
|
(6)
|
(1)
|
(123)
|
(27,646)
|
|
Current instalments of loans
|
|
(4,964)
|
2,004
|
-
|
2
|
-
|
(2,958)
|
|
Current instalments of leases
|
|
(228)
|
72
|
(2)
|
(73)
|
(1)
|
(232)
|
|
Commercial paper
|
|
-
|
(74)
|
-
|
-
|
-
|
(74)
|
|
Bank collateral received
|
|
(89)
|
(10)
|
-
|
-
|
-
|
(99)
|
|
Other short-term borrowings excluding overdrafts
|
|
(78)
|
(13)
|
-
|
-
|
1
|
(90)
|
|
Overdrafts
|
|
(183)
|
(218)
|
-
|
-
|
(3)
|
(404)
|
|
Total current debt
|
|
(5,542)
|
1,761
|
(2)
|
(71)
|
(3)
|
(3,857)
|
|
Gross borrowings
|
|
(29,232)
|
(2,065)
|
(8)
|
(72)
|
(126)
|
(31,503)
|
|
Net derivative financial instruments
|
|
(96)
|
(17)
|
-
|
92
|
-
|
(21)
|
|
Net borrowings
|
|
(29,328)
|
(2,082)
|
(8)
|
20
|
(126)
|
(31,524)
|
|
Cash and cash equivalents
|
|
6,166
|
74
|
-
|
-
|
(8)
|
6,232
|
|
Other investments - current
|
|
239
|
(9)
|
-
|
-
|
-
|
230
|
|
Cash and investments
|
|
6,405
|
65
|
-
|
-
|
(8)
|
6,462
|
|
Net debt
|
|
(22,923)
|
(2,017)
|
(8)
|
20
|
(134)
|
(25,062)
|
Non-cash movements in the period include fair value adjustments
under IFRS 9 Financial Instruments.
The Group has agreements with some bank counterparties whereby the
parties agree to post cash collateral on financial derivatives, for
the benefit of the other, equivalent to the market valuation of the
derivative positions above a predetermined threshold. The carrying
value of such cash collateral held by the Group at 31 March 2023
was $99m (31 December 2022: $89m) and the carrying value of such
cash collateral posted by the Group at 31 March 2023 was $164m (31
December 2022: $162m).
The equivalent GAAP measure to Net debt is 'liabilities arising
from financing activities', which excludes the amounts for cash and
overdrafts, other investments and non-financing derivatives shown
above and includes the Acerta Pharma share purchase liability of
$792m (31 December 2022: $1,646m), which is shown in current other
payables.
Net debt increased by $2,139m in the year to date to $25,062m.
Details of the committed undrawn bank facilities are disclosed
within the going concern section of Note 1.
During the three months ended 31 March 2023, there were no changes
to the Company's solicited credit ratings issued by Standard and
Poor's (long term: A; short term: A-1) and from Moody's (long term:
A3; short term: P-2).
Note 4: Financial Instruments
As detailed in the Group's most recent annual financial statements,
the principal financial instruments consist of derivative financial
instruments, other investments, trade and other receivables, cash
and cash equivalents, trade and other payables, lease liabilities
and interest-bearing loans and borrowings.
The Group has certain equity investments that are categorised as
Level 3 in the fair value hierarchy that are held at $217m at 31
March 2023 (31 December 2022: $186m) and for which fair value gains
of $1m have been recognised in the three months ended 31 March 2023
(31 March 2022: $nil). In the absence of specific market data,
these unlisted investments are held at fair value based on the cost
of investment and adjusting as necessary for impairments and
revaluations on new funding rounds, which are seen to approximate
the fair value. All other fair value gains and/or losses that are
presented in Net gains on equity investments measured at fair value
through other comprehensive income in the Condensed consolidated
statement of comprehensive income for the three months ended 31
March 2023 are Level 1 fair value measurements, valued based on
quoted prices in active markets.
Financial instruments measured at fair value include $1,162m of
other investments, $4,459m held in money-market funds, $291m of
loans designated at fair value through profit or loss and ($21m) of
derivatives as at 31 March 2023. With the exception of derivatives
being Level 2 fair valued, certain equity investments as described
above and an equity warrant of $20m categorised as Level 3, the
aforementioned balances are Level 1 fair valued. Financial
instruments measured at amortised cost include $61m of fixed
deposits and $164m of cash collateral pledged to counterparties.
The total fair value of interest-bearing loans and borrowings at 31
March 2023, which have a carrying value of $31,503m in the
Condensed consolidated statement of financial position, was
$30,576m.
Table 24:
Financial instruments - contingent
consideration
|
|
|
2023
|
2022
|
|||||
|
|
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|||
|
|
|
$m
|
$m
|
$m
|
$m
|
|||
|
At 1 January
|
|
2,124
|
98
|
2,222
|
2,865
|
|||
|
Additions through business combinations
|
|
-
|
60
|
60
|
-
|
|||
|
Settlements
|
|
(212)
|
(2)
|
(214)
|
(182)
|
|||
|
Disposals
|
|
-
|
-
|
-
|
(121)
|
|||
|
Discount unwind
|
|
31
|
2
|
33
|
42
|
|||
|
At 31 March
|
|
1,943
|
158
|
2,101
|
2,604
|
|||
|
|
|
|
|
|
|
|
|
|
Contingent consideration arising from business combinations is fair
valued using decision-tree analysis, with key inputs including the
probability of success, consideration of potential delays and the
expected levels of future revenues.
The contingent consideration balance relating to BMS's share of the
global diabetes alliance of $1,943m (31 December 2022:
$2,124m) would increase/decrease by $194m with an increase/decrease
in sales of 10%, as compared with the current
estimates.
Note 5: Legal proceedings and contingent liabilities
AstraZeneca is involved in various legal proceedings considered
typical to its business, including litigation and investigations,
including Government investigations, relating to product liability,
commercial disputes, infringement of intellectual property (IP)
rights, the validity of certain patents, anti-trust law and sales
and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures
concerning legal proceedings in the Company's Annual Report and
Form 20-F Information 2022 (the Disclosures).
As discussed in the Disclosures, the majority of claims involve
highly complex issues. Often these issues are subject to
substantial uncertainties and, therefore, the probability of a
loss, if any, being sustained and/or an estimate of the amount of
any loss is difficult to ascertain.
Unless specifically identified below, AstraZeneca considers each of
the claims to represent a contingent liability or a contingent
asset where the matter is brought by AstraZeneca, and discloses
information with respect to the nature and facts of the cases in
accordance with IAS 37.
There is one matter concerning legal proceedings in the
Disclosures, which is considered probable that an outflow will be
required, but for which we are unable to make an estimate of the
possible loss or range of possible losses at this
stage.
In cases that have been settled or adjudicated, or where
quantifiable fines and penalties have been assessed and which are
not subject to appeal, or where a loss is probable and we are able
to make a reasonable estimate of the loss, AstraZeneca records the
loss absorbed or makes a provision for its best estimate of the
expected loss. The position could change over time and the
estimates that the Company made, and upon which the Company have
relied in calculating these provisions are inherently imprecise.
There can, therefore, be no assurance that any losses that result
from the outcome of any legal proceedings will not exceed the
amount of the provisions that have been booked in the accounts. The
major factors causing this uncertainty are described more fully in
the Disclosures and herein.
AstraZeneca has full confidence in, and will vigorously defend and
enforce, its IP.
Matters disclosed in respect of the first quarter of 2023 and to 27
April 2023
Patent litigation
Enhertu
US patent proceedings
As previously disclosed, in December 2020 and January 2021,
AstraZeneca and Daiichi Sankyo, Inc. filed post-grant review (PGR)
petitions with the US Patent and Trademark Office (USPTO) alleging,
inter alia, that the Seagen patent is invalid for lack of written
description and enablement. The USPTO initially declined to
institute the PGRs, but, in April 2022, the USPTO granted the
rehearing requests, instituting both PGR petitions. Seagen
subsequently disclaimed all patent claims at issue in one of the
PGR proceedings. In July 2022, the USPTO reversed its institution
decision and declined to institute the other PGR petition.
AstraZeneca and Daiichi Sankyo, Inc. requested reconsideration of
the decision not to institute review of the patent. In February
2023, the USPTO reinstituted the PGR proceeding. An oral hearing is
scheduled for August 2023.
Lynparza
US patent proceedings
As previously disclosed, in December 2022, AstraZeneca received a
Paragraph IV notice letter from an abbreviated new drug application
(ANDA) filer relating to patents listed in the FDA Orange Book with
reference to Lynparza. In February 2023, in response to the Paragraph
IV notice, AstraZeneca, MSD International Business GmbH, and the
University of Sheffield initiated ANDA litigation against Natco
Pharma Limited (Natco) in the US District Court for the District of
New Jersey. In the complaint, AstraZeneca alleged that Natco's
generic version of Lynparza, if approved and marketed, would infringe patents
listed in the FDA Orange Book with reference
to Lynparza. No trial date has been
scheduled.
Movantik
US patent proceedings
AstraZeneca has resolved by settlement the previously disclosed
patent infringement lawsuit brought by Aether Therapeutics, Inc. in
the US District Court for the District of Delaware against
AstraZeneca, Nektar Therapeutics and Daiichi Sankyo, Inc., relating
to Movantik. This matter is now
concluded.
Symbicort
US patent proceedings
AstraZeneca has resolved via settlement the previously disclosed
ANDA litigations with Mylan Pharmaceuticals Inc. and Kindeva Drug
Delivery L.P. (together, the Defendants). In those actions,
AstraZeneca alleged that the Defendants' generic versions
of Symbicort, if approved and marketed, would infringe various
AstraZeneca patents. This matter is now
concluded.
Tagrisso
Patent proceedings outside the US
In Russia, in October 2021, AstraZeneca filed a lawsuit in the
Arbitration Court of the Moscow Region (the Court) against
Axelpharm, LLC to prevent it from obtaining authorisation to market
a generic version of Tagrisso prior to the expiration of AstraZeneca's
patents covering Tagrisso. The lawsuit also names the Ministry of Health of
the Russian Federation as a third party. In March 2022, the Court
dismissed the lawsuit. In June 2022, the dismissal was affirmed on
appeal. In January 2023, the dismissal was affirmed on further
appeal. This matter is now concluded.
Product liability litigation
Nexium and Losec/Prilosec
US proceedings
In the US, AstraZeneca is defending various previously disclosed
lawsuits brought in federal and state courts involving multiple
plaintiffs claiming that they have been diagnosed with various
injuries following treatment with proton pump inhibitors (PPIs),
including Nexium and Prilosec. The vast majority of those lawsuits relate to
allegations of kidney injuries. In August 2017, the pending federal
court cases were consolidated in a multidistrict litigation (MDL)
proceeding in the US District Court for the District of New Jersey
for pre-trial purposes. A bellwether trial has been scheduled for
October 2023, with subsequent bellwether trials scheduled for
November 2023 and January 2024. In addition to the MDL cases, there
are cases filed in several state courts around the US; a case that
was previously set to go to trial in Delaware state court was
dismissed in October 2022.
In addition, AstraZeneca has been defending various lawsuits
involving allegations of gastric cancer following treatment with
proton pump inhibitors (PPIs), including Nexium and Prilosec. One such claim is filed in the US District Court
for the Middle District of Louisiana has been scheduled to go to
trial in April 2024.
Onglyza and Kombiglyze
US proceedings
As previously disclosed, in the US, AstraZeneca is defending
various lawsuits alleging heart failure, cardiac injuries, and/or
death from treatment with Onglyza or Kombiglyze. In February 2018, the Judicial Panel on
Multidistrict Litigation ordered the transfer of various pending
federal actions to the US District Court for the Eastern District
of Kentucky (the District Court) for consolidated pre-trial
proceedings with the federal actions pending in the District Court.
The District Court granted AstraZeneca's motion for summary
judgment in August 2022, and plaintiffs are in the process of
appealing that decision. In the California State Court coordinated
proceeding, AstraZeneca's motion for summary judgment was granted
in March 2022. Plaintiffs appealed, and in April 2023, the
California Appellate Court affirmed the lower court's decision to
grant summary judgment.
Commercial Litigation
Viela Bio, Inc. Shareholder Litigation
US proceedings
In February 2023, AstraZeneca was served with a lawsuit filed in
the Delaware State Court against AstraZeneca and certain officers,
on behalf of a putative class of Viela Bio, Inc. (Viela)
shareholders. The complaint alleges that defendants breached their
fiduciary duty to Viela shareholders in the course of Viela's 2021
merger with Horizon Therapeutics, plc. This case remains in the
preliminary stages.
Definiens
In Germany, in July 2020, AstraZeneca received a notice
of arbitration filed with the German Institution of
Arbitration from the sellers of Definiens AG (the Sellers)
regarding the 2014 Share Purchase Agreement (SPA) between
AstraZeneca and the Sellers. The Sellers claim that they are
owed approximately $140m in earn-outs under the SPA. The
arbitration hearing took place in March 2023 and AstraZeneca awaits
a decision.
PARP Inhibitor Royalty Dispute
In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline
plc, 'GSK') entered into two worldwide, royalty-bearing patent
license agreements with AstraZeneca related to GSK's product
niraparib. In May 2021, AstraZeneca filed a lawsuit against GSK in
the Commercial Court of England and Wales alleging that GSK has
failed to pay all of the royalties due on niraparib sales under the
license agreements. The case was transferred to the Chancery
Division and a trial took place in March 2023. In April 2023, the
court issued a decision in AstraZeneca's favour.
Pay Equity Litigation (US)
AstraZeneca was defending a putative class and collective action
matter in the US District Court for the Northern District of
Illinois brought by three named plaintiffs, who are former
AstraZeneca pharmaceutical sales representatives. The case involved
claims under the federal and Illinois Equal Pay Acts, with the
plaintiffs alleging they were paid less than male employees who
performed substantially similar and/or equal work. The plaintiffs
sought various damages on behalf of themselves and the putative
class and/or collective, including without limitation backpay,
liquidated damages, compensatory and punitive damages, attorneys'
fees, and interest. In January 2023, the District Court granted
AstraZeneca's motion to dismiss plaintiffs' complaint. In March
2023, plaintiffs filed a Second Amended Complaint.
Portola Shareholder Litigation
In the US, in connection with Alexion's July 2020 acquisition of
Portola Pharmaceuticals, Inc (Portola), Alexion assumed litigation
to which Portola is a party. In January 2020, putative securities
class action lawsuits were filed in the US District Court for the
Northern District of California against Portola and certain
officers and directors, on behalf of purchasers of Portola publicly
traded securities during the period 8 January 2019 through 26
February 2020. The operative complaints allege that defendants made
materially false and/or misleading statements or omissions with
regard to Andexxa. In June 2022, the parties reached a settlement
in principle of this matter. In March 2023, the court granted final
approval of the settlement. This matter is now
concluded.
Alexion Shareholder Litigation (US)
In December 2016, putative securities class action lawsuits were
filed in the US District Court for the District of Connecticut (the
District Court) against Alexion and certain officers and directors,
on behalf of purchasers of Alexion publicly traded securities
during the period 30 January 2014 through 26 May 2017. The amended
complaint alleges that defendants engaged in securities fraud,
including by making misrepresentations and omissions in its public
disclosures concerning Alexion's Soliris sales practices, management changes, and
relateds investigations. In August 2021, the District Court issued
a decision denying in part Defendants' motion to dismiss the
matter. The Court granted Plaintiffs' motion for class
certification in April 2023.
Syntimmune
In connection with Alexion's prior acquisition of Syntimmune, Inc.,
(Syntimmune) in December 2020, Alexion was served with a lawsuit
filed by the stockholders' representative for Syntimmune in
Delaware State Court that alleged, among other things, breaches of
contractual obligations relating to the 2018 merger agreement. The
stockholders' representative alleges that Alexion failed to meet
its obligations under the merger agreement to use commercially
reasonable efforts to achieve the milestones. Alexion also filed a
claim for breach of the representations in the 2018 merger
agreement. A trial is scheduled for the matter in July
2023.
Government investigations/proceedings
Brazilian tax assessment
matter (Brazil)
As previously disclosed, in August 2019, the Brazilian Federal
Revenue Service provided a Notice of Tax and Description of the
Facts (the Tax Assessment) to two Alexion subsidiaries (the Brazil
Subsidiaries), as well as to two additional entities, a logistics
provider utilised by Alexion and a distributor. The Tax Assessment
focuses on the importation of Soliris vials pursuant to Alexion's free drug supply
to patients programme in Brazil.
Alexion prevailed in the first level of administrative appeals in
the Brazilian federal administrative proceeding system based on a
deficiency in the Brazil Tax Assessment. The decision was subject
to an automatic (ex officio) appeal to the second level of the
administrative courts. In March 2023, the second level of the
administrative courts issued a decision to remand the matter to the
first level of administrative courts for a determination on the
merits.
Note 6: Subsequent events
In April 2023, the contractual relationship between AstraZeneca and
Sobi relating to future sales of nirsevimab in the US was replaced
by a royalty relationship between Sanofi and Sobi. As a result, a
liability representing AstraZeneca's future obligations to Sobi
will be eliminated from AstraZeneca's Statement of Financial
Position, and AstraZeneca will record a gain of $718m in Core Other
operating income in Q2 2023.
Table 25: Q1 2023 - Product Sales year-on-year
analysis[73]
|
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|
|||||||||
|
|
$m
|
Act % chg
|
CER % chg
|
$m
|
% chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
$m
|
Act % chg
|
CER % chg
|
|
|
Oncology
|
3,920
|
16
|
21
|
1,704
|
24
|
966
|
8
|
16
|
760
|
17
|
24
|
490
|
4
|
19
|
|
|
Tagrisso
|
1,424
|
9
|
15
|
521
|
19
|
444
|
9
|
17
|
257
|
2
|
8
|
202
|
(2)
|
11
|
|
|
Imfinzi
|
900
|
50
|
56
|
522
|
66
|
81
|
39
|
47
|
163
|
31
|
38
|
134
|
33
|
52
|
|
|
Lynparza
|
651
|
5
|
10
|
268
|
(1)
|
137
|
13
|
19
|
178
|
11
|
18
|
68
|
2
|
16
|
|
|
Calquence
|
532
|
28
|
31
|
384
|
13
|
18
|
n/m
|
n/m
|
108
|
95
|
n/m
|
22
|
76
|
91
|
|
|
Enhertu
|
37
|
n/m
|
n/m
|
-
|
-
|
24
|
n/m
|
n/m
|
10
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
|
Orpathys
|
8
|
(33)
|
(27)
|
-
|
-
|
8
|
(33)
|
(27)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
Zoladex
|
227
|
(6)
|
3
|
3
|
(25)
|
167
|
-
|
10
|
33
|
(5)
|
1
|
24
|
(32)
|
(22)
|
|
|
Faslodex
|
75
|
(19)
|
(11)
|
4
|
(33)
|
37
|
(14)
|
(7)
|
10
|
(39)
|
(35)
|
24
|
(13)
|
1
|
|
|
Others
|
66
|
(32)
|
(27)
|
2
|
(28)
|
50
|
(31)
|
(27)
|
1
|
(55)
|
(52)
|
13
|
(32)
|
(22)
|
|
|
BioPharmaceuticals: CVRM
|
2,530
|
15
|
21
|
622
|
19
|
1,165
|
14
|
22
|
557
|
16
|
22
|
186
|
4
|
19
|
|
|
Farxiga
|
1,299
|
30
|
37
|
296
|
53
|
498
|
27
|
35
|
393
|
24
|
31
|
112
|
15
|
29
|
|
|
Brilinta
|
334
|
3
|
5
|
179
|
8
|
82
|
19
|
25
|
67
|
(12)
|
(7)
|
6
|
(59)
|
(53)
|
|
|
Lokelma
|
98
|
56
|
64
|
56
|
45
|
11
|
n/m
|
n/m
|
11
|
98
|
n/m
|
20
|
29
|
50
|
|
|
roxadustat
|
61
|
49
|
63
|
-
|
-
|
61
|
49
|
63
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
Andexxa
|
44
|
34
|
42
|
20
|
(13)
|
-
|
-
|
-
|
15
|
58
|
66
|
9
|
n/m
|
n/m
|
|
|
Crestor
|
305
|
14
|
23
|
14
|
(22)
|
241
|
22
|
32
|
16
|
48
|
56
|
34
|
(18)
|
(7)
|
|
|
Seloken/Toprol-XL
|
179
|
(27)
|
(20)
|
-
|
-
|
173
|
(27)
|
(21)
|
4
|
3
|
(3)
|
2
|
(23)
|
(19)
|
|
|
Onglyza
|
63
|
(8)
|
(3)
|
14
|
(26)
|
37
|
9
|
17
|
9
|
(17)
|
(17)
|
3
|
(32)
|
(17)
|
|
|
Bydureon
|
45
|
(33)
|
(32)
|
38
|
(32)
|
1
|
44
|
45
|
7
|
(38)
|
(34)
|
(1)
|
n/m
|
n/m
|
|
|
Others
|
102
|
4
|
9
|
5
|
(25)
|
61
|
19
|
27
|
35
|
(5)
|
(4)
|
1
|
(63)
|
(59)
|
|
|
BioPharmaceuticals: R&I
|
1,583
|
5
|
10
|
617
|
(4)
|
533
|
22
|
31
|
292
|
5
|
11
|
141
|
(6)
|
3
|
|
|
Symbicort
|
688
|
2
|
7
|
233
|
(10)
|
229
|
37
|
48
|
147
|
(6)
|
(1)
|
79
|
(14)
|
(7)
|
|
|
Fasenra
|
338
|
10
|
13
|
201
|
6
|
14
|
n/m
|
n/m
|
88
|
17
|
23
|
35
|
(4)
|
7
|
|
|
Breztri
|
144
|
67
|
73
|
81
|
53
|
38
|
71
|
85
|
15
|
n/m
|
n/m
|
10
|
52
|
73
|
|
|
Saphnelo
|
47
|
n/m
|
n/m
|
44
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
|
|
Tezspire
|
11
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
|
|
Pulmicort
|
221
|
2
|
9
|
10
|
(54)
|
182
|
11
|
19
|
20
|
12
|
19
|
9
|
(31)
|
(25)
|
|
|
Bevespi
|
15
|
(1)
|
2
|
9
|
(15)
|
2
|
9
|
21
|
4
|
55
|
64
|
-
|
-
|
-
|
|
|
Daliresp/Daxas
|
13
|
(75)
|
(75)
|
9
|
(80)
|
1
|
(19)
|
(17)
|
2
|
(6)
|
(2)
|
1
|
35
|
(36)
|
|
|
Others
|
106
|
(27)
|
(22)
|
30
|
(44)
|
67
|
(9)
|
(1)
|
8
|
(54)
|
(50)
|
1
|
(12)
|
(7)
|
|
|
BioPharmaceuticals: V&I
|
355
|
(80)
|
(78)
|
-
|
n/m
|
104
|
(84)
|
(83)
|
98
|
(66)
|
(64)
|
153
|
(66)
|
(62)
|
|
|
COVID-19 mAbs
|
127
|
(73)
|
(70)
|
-
|
n/m
|
8
|
(91)
|
(91)
|
4
|
(94)
|
(93)
|
115
|
n/m
|
n/m
|
|
|
Vaxzevria
|
28
|
(97)
|
(97)
|
-
|
n/m
|
18
|
(96)
|
(96)
|
10
|
(93)
|
(92)
|
-
|
n/m
|
n/m
|
|
|
Synagis
|
198
|
(1)
|
5
|
-
|
-
|
78
|
17
|
21
|
82
|
(5)
|
-
|
38
|
(18)
|
(7)
|
|
|
FluMist
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
|
|
Rare Disease
|
1,866
|
10
|
14
|
1,094
|
7
|
173
|
51
|
57
|
387
|
7
|
14
|
212
|
7
|
21
|
|
|
Soliris
|
834
|
(16)
|
(13)
|
448
|
(24)
|
115
|
63
|
77
|
183
|
(17)
|
(12)
|
88
|
(18)
|
(10)
|
|
|
Ultomiris
|
651
|
55
|
61
|
381
|
73
|
13
|
(46)
|
(45)
|
159
|
52
|
61
|
98
|
39
|
61
|
|
|
Strensiq
|
262
|
26
|
28
|
205
|
28
|
15
|
70
|
58
|
21
|
10
|
17
|
21
|
7
|
22
|
|
|
Koselugo
|
79
|
n/m
|
n/m
|
41
|
34
|
24
|
n/m
|
n/m
|
11
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
|
|
Kanuma
|
40
|
4
|
6
|
19
|
3
|
6
|
(1)
|
(6)
|
13
|
5
|
10
|
2
|
31
|
44
|
|
|
Other medicines
|
312
|
(26)
|
(21)
|
36
|
(8)
|
205
|
-
|
8
|
22
|
(38)
|
(37)
|
49
|
(66)
|
(62)
|
|
|
Nexium
|
244
|
(27)
|
(20)
|
29
|
(12)
|
156
|
8
|
17
|
12
|
(19)
|
(15)
|
47
|
(67)
|
(62)
|
|
|
Others
|
68
|
(26)
|
(23)
|
7
|
19
|
49
|
(18)
|
(13)
|
10
|
(52)
|
(52)
|
2
|
(63)
|
(58)
|
|
|
Total Product Sales
|
10,566
|
(4)
|
1
|
4,073
|
2
|
3,146
|
(5)
|
2
|
2,116
|
1
|
7
|
1,231
|
(23)
|
(13)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table 26:
Alliance Revenue
|
|
|
Q1 2023
|
Q1 2022
|
|
|
|
$m
|
$m
|
|
Enhertu
|
|
220
|
76
|
|
Tezspire
|
|
43
|
3
|
|
Vaxzevria: royalties
|
|
-
|
56
|
|
Other royalty income
|
|
20
|
16
|
|
Other Alliance Revenue
|
|
3
|
1
|
|
Total
|
|
286
|
152
|
Table 27:
Collaboration Revenue
|
|
|
Q1 2023
|
Q1 2022
|
|
|
|
$m
|
$m
|
|
Lynparza: regulatory
milestones
|
|
-
|
175
|
|
Farxiga: sales
milestones
|
|
24
|
-
|
|
tralokinumab: sales milestones
|
|
-
|
70
|
|
Other Collaboration Revenue
|
|
3
|
13
|
|
Total
|
|
27
|
258
|
Table 28:
Other Operating Income and Expense
|
|
|
Q1 2023
|
Q1 2022
|
|
|
|
$m
|
$m
|
|
brazikumab licence termination funding
|
|
38
|
35
|
|
Divestment of US rights to Pulmicort Flexhaler
|
|
241
|
-
|
|
Other
|
|
100
|
62
|
|
Total
|
|
379
|
97
|
Other shareholder information
Financial calendar
Announcement of half year and second quarter 2023 results:
28 July 2023
Announcement of nine month and third quarter 2023 results: 9
November 2023
Announcement of full year and fourth quarter 2023 results: 8
February 2024
Dividends are normally paid as follows:
First interim: Announced with the half year results and paid
in September
Second interim: Announced with full year results and paid in
March
The record date for the first interim dividend for 2023, payable on
11 September 2023, will be 11 August 2023. The ex-dividend date
will be 10 August 2023.
Contacts
For details on how to contact the
Investor Relations Team, please click
here. For Media
contacts, click
here.
Addresses for correspondence
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
|
db@astfinancial.com
|
Trademarks
Trademarks of the AstraZeneca group of companies appear throughout
this document in italics. Medical publications also appear
throughout the document in italics. AstraZeneca, the AstraZeneca
logotype and the AstraZeneca symbol are all trademarks of the
AstraZeneca group of companies. Trademarks of companies other than
AstraZeneca that appear in this document
include Arimidex and Casodex,
owned by AstraZeneca or Juvisé (depending on
geography); Beyfortus, a trademark of Sanofi Pasteur
Inc.; Enhertu, a trademark of Daiichi Sankyo; Losec,
owned by AstraZeneca or Cheplapharm (depending upon
geography); Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd
(depending on geography); Synagis, owned by AstraZeneca or Sobi aka Swedish Orphan
Biovitrum AB (publ). (depending on
geography); and Tezspire, a trademark of Amgen, Inc.
Information on or accessible through AstraZeneca's websites,
including astrazeneca.com,
does not form part of and is not incorporated into this
announcement.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Cautionary statements regarding forward-looking
statements
In order, among other things, to utilise the 'safe harbour'
provisions of the US Private Securities Litigation Reform Act of
1995, AstraZeneca (hereafter 'the Group') provides the following
cautionary statement:
This document contains certain forward-looking statements with
respect to the operations, performance and financial condition of
the Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group's
control, include, among other things:
-
the risk of failure to meet regulatory or ethical requirements for
medicine development or approval
-
the risk of failures or delays in the quality or execution of the
Group's commercial strategies
-
the risk of pricing, affordability, access and competitive
pressures
-
the risk of failure to maintain supply of compliant, quality
medicines
-
the risk of illegal trade in the Group's medicines
-
the impact of reliance on third-party goods and
services
-
the risk of failure in information technology or
cybersecurity
-
the risk of failure of critical processes
-
the risk of failure to collect and manage data in line with legal
and regulatory requirements and strategic objectives
-
the risk of failure to attract, develop, engage and retain a
diverse, talented and capable workforce
-
the risk of failure to meet regulatory or ethical expectations on
environmental impact, including climate change
-
the risk of the safety and efficacy of marketed medicines being
questioned
-
the risk of adverse outcome of litigation and/or governmental
investigations
-
intellectual property-related risks to our products
-
the risk of failure to achieve strategic plans or meet targets or
expectations
-
the risk of failure in financial control or the occurrence of
fraud
-
the risk of unexpected deterioration in the Group's financial
position
-
the impact that global and/or geopolitical events such as the
COVID-19 pandemic and the Russia-Ukraine war may have or continue
to have on these risks, on the Group's ability to continue to
mitigate these risks, and on the Group's operations, financial
results or financial condition
Nothing in this document, or any related presentation/webcast,
should be construed as a profit forecast.
- End of document -
[1] The COVID-19 medicines
are Vaxzevria, Evusheld, and AZD3152 - the COVID-19 antibody currently in
development.
[2] Constant exchange
rates. The differences between Actual Change and CER Change are due
to foreign exchange movements between periods in 2023 vs 2022. CER
financial measures are not accounted for according to generally
accepted accounting principles (GAAP) because they remove the
effects of currency movements from Reported
results.
[3] Effective 1 January
2023, the Group has updated the presentation of Total Revenue. For
further details of the presentation of Alliance Revenue and
Collaboration Revenue, see the basis of preparation and accounting
policy section of the Notes to the Interim Financial Statements
section.
[4] Reported financial
measures are the financial results presented in accordance with
UK-adopted International Accounting Standards and International
Financial Reporting Standards (IFRSs) as issued by the
International Accounting Standards Board (IASB) and International
Accounting Standards as adopted by the European
Union.
[5] Earnings per
share.
[6] Core financial
measures are adjusted to exclude certain items. The differences
between Reported and Core measures are primarily due to costs
relating to the acquisition of Alexion, amortisation of
intangibles, impairments and restructuring charges. A full
reconciliation between Reported EPS and Core EPS is provided in
Table 13 in the Financial performance section of this
document.
[7] Cardiovascular, Renal
and Metabolism.
[8] Respiratory &
Immunology.
[9] Non-small cell lung
cancer.
[10] Hepatocellular
carcinoma.
[11] Neuromyelitis optica
spectrum disorder.
[12] Human epidermal growth
factor receptor 2.
[13] nirsevimab is approved in
the EU with the Beyfortus trademark.
[14] Vaxzevria is AstraZeneca's trademark for the Company's
supply of the AstraZeneca COVID-19 Vaccine. In the financial tables
in this report, 'Vaxzevria Total Revenue' includes royalties from
sub-licensees that produce and supply the AstraZeneca COVID-19
Vaccine under their own trademarks, recorded in Alliance
Revenue.
[15] Monoclonal antibodies. The
COVID-19 mAbs are Evusheld and AZD3152.
[16] For Alliance Revenue and
Collaboration Revenue, the comparable amounts for FY 2022 are $749m
and $604m respectively.
[17] Vaccines & Immune
Therapies.
[18] In Table 2, the plus and
minus symbols denote the directional impact of the item being
discussed, e.g. a '+' symbol next to an R&D expense comment
indicates that the item increased the R&D expense relative to
the prior year.
[19] The calculation of
Reported and Core Gross Margin excludes the impact of Alliance
Revenue and Collaboration Revenue.
[20] Income from disposals of
assets and businesses, where the Group does not retain a
significant ongoing economic interest, continue to be recorded in
Other Operating Income and Expense in the Company's financial
statements.
[21] Respiratory syncytial
virus.
[22] Hereditary
transthyretin-mediated amyloid polyneuropathy.
[23] Hormone
receptor.
[24] Taskforce on
Climate-related Financial Disclosures.
[25] Product Sales shown
in the Imfinzi line include Product Sales
from Imjudo
[26] National
reimbursement drug list.
[27] France, Germany,
Italy, Spain, UK.
[28] Biliary tract
cancer.
[29] Extensive-stage small
cell lung cancer.
[30] Poly ADP ribose
polymerase.
[31] Platinum sensitive
relapse
[32] Breast cancer gene
mutation.
[33] Germline (hereditary)
breast cancer gene mutation.
[34] Metastatic breast
cancer.
[35] Bruton tyrosine
kinase inhibitor.
[36] Mesenchymal-epithelial
transition.
[37] Sodium-glucose
cotransporter 2.
[38] Heart
failure.
[39] Chronic kidney
disease.
[40] European Society of
Cardiology.
[41] American Heart
Association.
[42] American College of
Cardiology.
[43] Heart Failure Society
of America.
[44] Heart failure with
reduced ejection fraction.
[45] Type-2
diabetes.
[46] Heart failure with
preserved ejection fraction.
[47] Betaloc is the brand name
for Seloken in China.
[48] Inhaled
corticosteroid.
[49] Long-acting
beta-agonist.
[50] Interleukin-5.
[51] The 'dynamic market'
refers to patients who have recently changed their medicine. For
biologic medicines, it captures patients who have adopted a
biologic medicine for the first time, and patients who have
switched from one biologic brand to another.
[52] Fixed dose
combination.
[53] 'New-to-brand' share
represents a medicine's share in the dynamic
market
[54] Asthma COPD
overlap.
[55] Intravenous
injection.
[56] Systemic lupus
erythematosus.
[57] Complement component
5.
[58] Atypical haemolytic
uraemic syndrome.
[59] Generalised
myasthenia gravis.
[60] Other Operating
Income.
[61] Securities Exchange
Commission.
[62] Based on best
prevailing assumptions around currency
profiles.
[63] Based on average
daily spot rates 1 Jan 2022 to 31 Dec 2022.
[64] Based on average
daily spot rates 1 Jan 2023 to 31 Mar 2023.
[65] Based on average
daily spot rates 1 Mar 2023 to 31 Mar 2023.
[66] Change vs the average
spot rate for the previous year
[67] Other currencies
include AUD, BRL, CAD, KRW and RUB.
[68] Overall
survival.
[69] Epidermal growth
factor receptor mutation.
[70] Supplemental new drug
application.
[71] Neutralising
antibody.
[72] Effective 1 January
2023, the Group has updated the presentation of Total Revenue. See
Note 1 for further details of the presentation of Alliance
Revenue.
[73] The table provides an
analysis of year-on-year Product Sales, with Actual and CER growth
rates reflecting year-on-year growth. Due to rounding, the sum of a
number of dollar values and percentages may not agree to
totals.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
27 April 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|